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INTRODUCTION 
 
 
Tuberous sclerosis complex (TSC) is an autosomal dominant genetic disease of pediatric onset 
affecting multiple organ systems, including the kidney, brain, retina, heart, skin, and lungs (Northrup and 
Krueger 2013). It is estimated to affect at least 1/10,000 births (O'Callaghan et al 1998, Sampson et al 
1989). TSC is characterized by hamartomas or benign tumor growths in the affected organs. The most 
debilitating symptoms in TSC are a consequence of brain involvement, including a high rate of epilepsy, 
autism spectrum disorder, and learning disabilities (Sahin et al 2016). TSC is caused by mutations in 
either the TSC1 or TSC2 genes, which encode the proteins hamartin and tuberin, respectively (1993, van 
Slegtenhorst et al 1997). Hamartin and Tuberin bind together to negatively regulate mechanistic target of 
rapamycin complex 1 (mTORC1). Genetic loss of TSC1 or TSC2 leads to elevated and constitutively 
active mTORC1 signaling that impacts multiple processes, including cell growth and protein translation. 
Hamartomas in TSC are generally thought to arise from a “second-hit” somatic mutation in the 
other allele of TSC1 or TSC2, resulting in unhindered growth but leaving the surrounding heterozygous 
tissue functionally normal. While this model is supported by existing data in kidney and lung samples, 
molecular analyses of cortical hamartomas in the brain (“tubers”) demonstrate few cells with loss of 
heterozygosity (Henske et al 1996, Martin et al 2017, Niida et al 2001, Qin et al 2010). Furthermore, 
imaging and pathologic data indicate abnormalities also exist in non-hamartomatous regions including 
decreased grey matter volume, abnormal white matter tracts, focal dyslamination, and dysplastic neurons 
(Chandra et al 2007, Lewis et al 2013, Marcotte et al 2012, Peters et al 2012, Ridler et al 2001). 
Developmental brain abnormalities have also been detected in TSC patients as early as 20 weeks of 
gestation (Muhler et al 2007, Park et al 1997, Prabowo et al 2013, Tsai et al 2014). These results indicate 
an important role for mutations of TSC1 and TSC2 genes contributing to abnormal neural development. 
To better understand the impact of TSC2 loss on development, we generated induced pluripotent 
stem cells (iPSCs) using human dermal fibroblasts obtained from TSC patients and control volunteers. In 
addition to these heterozygous TSC2 lines, we generated homozygous TSC2 iPSCs using CRISPR-Cas9 
technology to edit the genome. The following chapters detail what we have learned from human 
fibroblast, stem cell, and neural progenitor models of TSC2 mutations. Chapter I will describe the clinical 
presentation of TSC and the current understanding of the molecular functions of TSC1, TSC2, and mTOR. 
Chapter II provides evidence for an unexpected finding of heterozygous TSC2 mutations hindering the 
reprograming process and discusses what can be learned from heterozygous patient fibroblasts. Chapter 
III explores how heterozygous TSC mutations or integration of the OCT4/shp53 plasmid may alter stem 
cell biology. Chapter IV focuses on neural differentiation of TSC stem cells and how heterozygous or 
homozygous mutations in TSC2 affect formation of neural progenitors. Finally, Chapter V places these 
results in a broader context and considers what questions remain. 
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CHAPTER I 
 
CLINICAL PRESENTATION OF TUBEROUS SCLEROSIS COMPLEX AND 
MOLECULAR FUNCTION OF TSC1 AND TSC2 
 
Tuberous Sclerosis Complex 
 
The first descriptions of tuberous sclerosis complex may have been as early as 1835 when 
dermatologists described a papule eruption over the nose and cheeks in a butterfly pattern (Rayer 1835). It 
was not until 1862-1908 that a more complete clinical description included the pathological findings of 
cardiac rhabdomyomas and cortical tubers/scleromas in patients with intellectual disability and epilepsy 
(Bourneville 1880, Hartdegen 1881, Vogt 1908, Von Recklinghausen 1862). Bourneville named the 
disease “Tuberous sclerosis of cerebral convolutions” after the hard (sclerotic) cortical tubers 
(Bourneville 1880). Later, Vogt established the first diagnostic criteria for TSC: intellectual disability, 
epilepsy, and facial angiofibromas (Vogt 1908). Following this initial triad of symptoms, the range of 
clinical presentations and variable expressivity of the disease became evident. The diagnostic criteria, 
updated in 2013, now include genetic testing as well as dermatologic, cortical, renal, retinal, cardiac, and 
pulmonary manifestations (Table 1.1) (Northrup and Krueger 2013). 
 Diagnostic Criteria  Prevalence in TSC Onset 
Major Hypomelanotic macules (3, at least 5mm) 90% birth 
Major Angiofibromas (3) or fibrous cephalic plaque 75%/25% childhood 
Major Ungual fibromas (2) 20% >10 years 
Major Shagreen patch 50% <10 years 
Major Multiple retinal hamartomas 30-50%   
Major Tubers or white matter radial migration lines 90%/40% prenatal 
Major Subependymal nodules 80% prenatal 
Major Subependymal giant cell astrocytoma 5-15% birth to adolescence 
Major Cardiac rhabdomyoma 50% prenatal 
Major Lymphangioleiomyomatosis 30-40% (female) >18 years 
Major Angiomyolipomas (2) 80% <10 years 
        
Minor "Confetti" skin lesions 3-58% <10 years 
Minor Dental enamel pits (>3) 100% increase with age 
Minor Intraoral fibromas (>2) 20-50% increase with age 
Minor Retinal achromic patch 39%   
Minor Multiple-renal cysts     
Minor Non-renal hamartomas     
Table 1.1 Diagnostic Criteria of Tuberous Sclerosis (2 major or 1 major and 2 minor)  
Cardiac rhabdomyomas can be detected by prenatal ultrasound and have a 75-80% positive 
predictive value (Hinton et al 2014, Northrup and Krueger 2013). This allows for early identification of 
patients and, potentially, early treatment. Interestingly, the onset and potential for continued growth varies 
between hamartomas. For example, cardiac rhabdomyomas have an exclusively prenatal onset and 
frequently regress postnatally. Cortical tubers appear prenatally and appear to be static in number and 
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size; however, there is evidence for increasing calcification of tubers throughout life. Even within the 
same organ, lesions may have different patterns of growth; in contrast to tubers, subependymal nodules 
(SEN) in the brain can continue to grow until adolescence and in some cases progress to subependymal 
giant cell astrocytomas (SEGA). Angiomyolipomas (AML) and facial angiofibromas have a later onset in 
childhood and may continue to progress throughout life. Pulmonary lymphangioleiomyomatosis (LAM), 
meanwhile, almost only appears in female patients after puberty. This suggests that there may be different 
molecular mechanisms for hamartoma development depending on the targeted organ. 
The phenotype-genotype correlation in TSC patients is poor; patients with the same or similar 
mutations even within the same family can present with drastically different disease burdens. Most 
patients with TSC have a near normal life expectancy; however, the mortality in patients with TSC differs 
significantly between patients with more or less severe disease manifestations. In the most recent study 
examining causes of death in TSC, 284 patients were divided into two groups based on the presence or 
absence of learning disabilities (Amin et al 2016). Mortality was significantly more common in TSC 
patients with learning disabilities; however, no patients in the study died before 16 years of age, 
regardless of which group they were in. The most common causes of death related to TSC were 
complications of renal pathology (50%, chronic kidney disease, polycystic kidney disease, hemorrhage, 
renal cell carcinoma). Next was sudden unexplained death in epilepsy (25%), followed by pulmonary 
complications (heart failure, hemorrhage), hydrocephalus and metastatic pancreatic disease (Amin et al 
2016). The TSC2 gene is located upstream of the polycystic kidney disease gene, PKD1, and large 
deletions affecting both genes can occur, leading to more severe kidney disease.  
The most debilitating symptoms are a consequence of the brain involvement in TSC. The most 
common symptoms are epilepsy (75%), intellectual disability (50%), and other behavioral problems, 
including autism and ADHD (40%) (Jones et al 1999). Epilepsy in TSC usually presents in the first year 
and is frequently refractory to anti-seizure medications (Chu-Shore et al 2010). Treatments for refractory 
epilepsy include surgery or possibly TSC signaling specific agents (mTORC1 inhibitors) (Feliciano et al 
2013). 
Reports of cases of TSC in families led to the conclusion that TSC was caused by an inherited 
genetic mutation and, further, it was inherited in an autosomal dominant manner (Fuhs 1925, Gunther and 
Penrose 1935).  However, the causative genes were not identified until 1993 and 1997 (1993, van 
Slegtenhorst et al 1997). The known genetic cause makes TSC a tractable model for understanding the 
pathogenesis of less genetically defined disorders like autism or epilepsy. 
 
Neuropathology 
 
The most common neuropathological features of TSC are cortical tubers, subependymal nodules 
(SEN), or subependymal giant cell astrocytomas (SEGA). Other findings include dysplastic neurons 
throughout the brain, radial glial lines, and white matter tract abnormalities. Tubers can be found in any 
lobe of the cortex, subcortical white matter, or cerebellum. They vary widely in distribution and size, even 
within an individual patient. There is some evidence of a correlation between neurological symptoms and 
tuber number, size, and/or location. Tuber burden (number and total volume) correlates with intellectual 
disability (Goodman et al 1997, Jansen et al 2008b). Tubers located in the cerebellum or the temporal 
lobe correlate with autism spectrum disorder (Bolton et al 2002, Eluvathingal et al 2006, Jambaque et al 
1991). 
Histologically, tubers and SEGAs display a mix of glial and neuronal markers and morphology. 
Tubers have disorganized cortical lamination with marked gliosis and inflammation with infiltration of T 
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cells and microglial activation (Muhlebner et al 2016). Giant cells in the tubers stain positive for neural 
progenitor or astrocyte markers and phospho-S6, suggesting abnormal differentiation and activation of 
mTORC1. There is some evidence for decreased myelin within tubers and decreased numbers of 
oligodendrocytes (Muhlebner et al 2016, Scholl et al 2016). Tubers have been identified as early as 20 
weeks gestation; the number and size of tubers do not change postnatally. This suggests that tubers may 
form during normal cortical proliferation and development when neural progenitors are most active. 
However, that does not mean the cortical tubers are completely static, as they can become calcified over 
time (Altman et al 1988, Koh et al 2000, Muhlebner et al 2016). Subependymal nodules (SEN) are 
localized along the ventricle wall, especially near the foramen of Monro. Subependymal giant cell 
astrocytomas (SEGA) are thought to progress from SENs, although it is not currently possible to predict 
which SENs will progress to SEGAs. SEGAs also contain enlarged neurons and multinucleated cells 
which stain positively for neural progenitor or astrocyte markers (Buccoliero et al 2009, Ess et al 2005, 
Hirose et al 1995, Lopes et al 1996). The precise cellular progenitors of tubers and SEGAs are unclear, 
but the continued expression of neural progenitor and astrocyte markers suggest abnormal neural 
differentiation contributes to the pathology. 
There is also evidence for neuropathological abnormalities outside of the hamartomatous growths 
in the brain. Diffusion tensor imaging of TSC patients reveals white matter abnormalities even in 
apparently “normal” areas of the brain. Patients have increased apparent diffusion coefficient values 
(reflecting total diffusion), decreased fractional anisotropy (reflecting directional diffusion), and increased 
radial diffusivity (reflecting diffusion out of the main axis, orthogonal to the axon) (Arulrajah et al 2009, 
Garaci et al 2004, Krishnan et al 2010, Makki et al 2007, Simao et al 2010, Widjaja et al 2010). All three 
of these measurements together suggest decreased white matter integrity and impaired neuronal 
connectivity in TSC.  
 
Genetics of TSC 
 
 The causative genes in TSC, named TSC1 and TSC2, were identified in 1997 and 1993, 
respectively (1993, van Slegtenhorst et al 1997). Subsequently, it was shown that the TSC1 gene product, 
hamartin, and the TSC2 gene product, tuberin, form a complex along with TBC1D7 which inhibits 
mTORC1 via Rheb (ras homolog enriched in brain). Tuberin contains a GTPase activating (GAP) domain 
which converts Rheb-GTP to Rheb-GDP while hamartin is thought to function primarily as a scaffolding 
protein. 
TSC1 is located on chromosome 9 and is transcribed into a 23 exon 8.6kb transcript. The protein, 
hamartin, is 1164 amino acids and 130kDa. Human hamartin protein is 20% identical to Drosophila, 
49%/41% identical to zebrafish tsc1a/tsc1b, 87% identical to mouse, 86% identical to rat, and 99% 
identical to chimpanzee orthologues (ensembl). TSC2 is located on chromosome 16 which is transcribed 
into a 42 exon 5.5kb transcript. By convention, the exons of TSC2 are numbered 1-41 with the 
untranslated leader exon designated as 1a. The protein, tuberin, is 1807 amino acids and 200kDa. Human 
TSC2 protein is 31% identical to Drosophila, 56% identical to zebrafish, 88% identical to mouse, 91% 
identical to rat, and 98% identical to chimpanzee orthologues (ensembl). 
There is evidence to support two alternative transcripts of TSC2 missing exon 25 and/or exon 31 
that are expressed in both adult and fetal tissue in humans, as well as other species (Ekong et al 2016, 
Kobayashi et al 1995, Maheshwar et al 1996, Xu et al 1995). Exon 31 is less well-conserved than the 
other exons of TSC2. Furthermore, no pathogenic mutations have been identified in either exon 25 or 31. 
This suggests that any functions of these exons are dispensable for the pathogenesis of TSC (Ekong et al 
2016). 
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Mutations are identifiable in 80-90% of patients with TSC, and, given the marked improvements 
in sequencing technology, there is growing evidence that the majority of remaining patients have 
causative mutations that were initially undetected because they were mosaic or localized to introns (Jones 
et al 1999, Tyburczy et al 2015).  In TSC patients, mutations in TSC2 are ~3-4x more common than 
mutations in TSC1 (Jones et al 1999, Niida et al 2001, Sancak et al 2005). TSC is inherited in families in 
an autosomal dominant manner one third of the time, with the remaining cases being de novo (Jones et al 
1999). In contrast to the overall pattern of TSC2 versus TSC1 mutations, in cases of familial inheritance 
approximately half are linked to mutations in TSC1 (Niida et al 2001, Povey et al 1994). Although 
TBC1D7 binds to the tuberin/hamartin complex and loss-of-function results in increased mTORC1 
signaling, mutations in the TBC1D7 gene do not cause tuberous sclerosis complex (Dibble et al 2012). 
The types of mutations seen in patients in TSC1 versus TSC2 also hint at the differences in 
function. Consistent with the role of hamartin as a scaffolding protein, missense mutations are not 
commonly pathogenic (1%). Instead, nonsense, frameshift, or splice-site mutations account for almost all 
the pathogenic mutations identified; these would be expected to significantly alter protein sequence or 
decrease protein levels (Jones et al 1999, Sancak et al 2005). In contrast, the mutations identified in TSC2 
display a much wider variety. Although the majority of mutations (72-75%) show larger changes 
(nonsense, frameshift, large rearrangements, splice site), there are a significant number of missense 
mutations and in-frame indels (insertion/deletions). Unsurprisingly, many missense mutations occurred in 
the GAP domain (exon 34-38), presumably impairing regulation of Rheb (Jones et al 1999, Niida et al 
2001, Sancak et al 2005). However, the highest mutation rate is found in exons 16 and 40, which are not 
part of any particular domain in the tuberin protein (Jones et al 1999, Kwiatkowski et al 2011, Sancak et 
al 2005). It is unclear why these two exons are disproportionately affected in TSC2 mutations. The 
difference in mutation types seen in TSC1 versus TSC2 suggest that TSC2 is more sensitive to genetic 
alterations; this may partially explain why more patients are identified with mutations in TSC2. Mutations 
in TSC1 or TSC2 do not predispose for increasing rates of somatic mutations, which is consistent with the 
normal rate of carcinomas in TSC patients (Martin et al 2017). 
Attempts to correlate the phenotype and genotype have led to the conclusion that mutations in 
TSC are highly penetrant but with variable expressivity, such that even identical mutations in twins 
present with different symptoms (Humphrey et al 2004). Mutations in TSC2 correlate with increased 
severity of disease including intellectual disability and tuber burden (Sancak et al 2005). This is consistent 
with the increased rate of TSC2 mutations in sporadic cases (increased likelihood of presentation with 
more severe disease) and the increased rate of TSC1 mutations in familial cases (increased likelihood of 
reproduction with less severe disease). 
A major hypothesis in this field is that the hamartomatous growths in TSC occur following a 
second-hit or loss-of-heterozygosity (LOH) in the other allele, consistent with a tumor suppressor 
pathway. This helps explain the variability in patient presentations: the occurrence of somatic second-hits 
occurs randomly and, depending on when and where during development they occur, resulting signs and 
symptoms could be dissimilar. This hypothesis has been confirmed in renal angiomyolipomas, 
hypopigmented macule melanocytes, facial angiofibromas, cephalic fibrous plaques, and subependymal 
giant cell astrocytomas (Cao et al 2017, Li et al 2011, Martin et al 2017, Tyburczy et al 2014). 
Interestingly, the types of second-hit mutations found in angiofibromas were consistent with UV-induced 
damage, suggesting that sun exposure contributes to second-hits and explaining why the appearance and 
number of angiofibromas increase with age (Tyburczy et al 2014). In contrast, molecular analyses of 
cortical tubers demonstrate few cells with loss of heterozygosity (Henske et al 1996, Martin et al 2017, 
Niida et al 2001, Qin et al 2010). Furthermore, the giant cells seen in cortical tubers are electrically silent, 
suggesting that if they do contribute to seizure activity, it is not as the primary electrical source (Cepeda, 
Andre, Vinters et al. 2005; Cepeda, Andre, Flores-Hernandez et al. 2005). 
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Hamartin and Tuberin Protein Function 
 
 TSC1 and TSC2 have been shown to encode the proteins hamartin and tuberin respectively. Initial 
insights into the function of tuberin came after Tsc2 was identified as the causative mutation in the Eker 
rat, a model of hereditary renal cell carcinoma first described in 1954 (Eker 1954, Yeung et al 1994). 
Following identification of the human TSC2 gene, similarities between the protein sequence of TSC2 in 
exon 37 and the GTPase-activating protein GAP3 led authors to hypothesize that tuberin may have GAP 
activity (1993). GAPs inhibit G proteins by binding and enhancing conversion of GTP to GDP, thus 
shifting the G protein to its inactive state. Tuberin was later confirmed to bind to Rheb and inhibit its 
activity (Inoki et al 2003a, Tee et al 2003). 
 Other domains identified in tuberin include the hydrophobic potential leucine zipper domain 
(exons 3-4), and two coiled-coil domains (exons 10-11 and exon 26). The hydrophobic/leucine zipper 
domain and the first coiled-coil domain of tuberin were identified as the hamartin binding domains (van 
Slegtenhorst et al 1998). Hamartin protein contains a coiled-coil domain in exon 17-23 which corresponds 
to the tuberin binding domain (van Slegtenhorst et al 1998). Hamartin also contains a transmembrane 
domain in the N-terminal region of the protein. The two proteins form a complex along with TBC1D7 
which localizes to the lysosome, perinuclear region, Golgi apparatus, and cytoplasmic vesicles. Tuberin 
and hamartin are constitutively expressed in all cells, supporting their fundamental role in regulating cell 
growth and differentiation (1993). Homozygous knockouts of TSC1 or TSC2 result in embryonic lethality 
in mice. 
Hamartin and tuberin act upstream to inhibit mTORC1 (Figure 1.1). The TSC complex regulates 
mTORC1 by localizing to the lysosomal surface where tuberin binds to Rheb GTPase and inhibits the 
protein by promoting switching from the active GTP-bound state to the inactive GDP-bound state (Inoki 
et al 2003a, Menon et al 2014, Tee et al 2003). Rheb activates mTORC1 by phosphorylating mTOR. 
There is crosstalk between several proteins important for transmitting growth factor signals (Akt, ERK, 
Wnt) and mTORC1 in order to coordinate cell growth and proliferation. Akt, ERK, and Wnt activate 
mTORC1 by phosphorylating tuberin to disrupt TSC complex binding and localization, releasing 
mTORC1 from TSC complex inhibition (Inoki et al 2002, Inoki et al 2006, Ma et al 2005, Manning et al 
2002, Potter et al 2002, Roux et al 2004). Additionally, Akt can phosphorylate PRAS40 independently of 
TSC1/TSC2 to relieve inhibition of mTORC1(Kovacina et al 2003, Sancak et al 2007, Vander Haar et al 
2007). Signals of stress, when the cell needs to slow down proliferation and anabolic processes, activate 
TSC2 or TSC1 to inhibit mTORC1. Low energy via AMPK, hypoxia via REDD1, or DNA damage via 
p53 activate or increase expression of tuberin or hamartin in order to inhibit mTORC1 driven growth 
(Brugarolas et al 2004, Budanov and Karin 2008, DeYoung et al 2008, Feng et al 2005, Feng et al 2007, 
Inoki et al 2003b). Homozygous loss of tuberin or hamartin disrupts this important regulatory node 
resulting in constitutively active mTORC1 signaling regardless of the inhibitory or stimulatory signals.  
TBC1D7 binds to TSC1 to stabilize the hamartin-tuberin complex. Knockdown of TBC1D7 
decreases hamartin-tuberin binding, leading to growth-factor independent activation of mTORC1 similar 
to loss of hamartin or tuberin (Dibble et al 2012, Nakashima et al 2007).  Although mutations in TBC1D7 
in patients cause elevated mTORC1 signaling, they do not cause TSC; instead, homozygous mutations 
cause autosomal recessive macrocephaly (Alfaiz et al 2014, Capo-Chichi et al 2013). 
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Figure 1.1 TSC Pathway 
 
mTOR complex 1and mTOR complex 2 
 
 Mechanistic target of rapamycin (mTOR) is a 289-kDa serine/threonine kinase, which forms two 
complexes called mTORC1 and mTORC2. mTORC1 is composed of the proteins mTOR, raptor, pras40, 
deptor, mLST8 and Tti1/Tel2. Raptor (regulatory-associated protein of mammalian target of rapamycin) 
is a scaffolding protein which regulates mTORC1 localization and substrate binding. The Tt1/Tel2 
complex is a scaffold regulating mTORC1 stability. Proline-rich Akt substrate 40kDa (PRAS40) and DEP 
domain containing mTOR-interacting protein (DEPTOR) are mTORC1 inhibitors. Mammalian lethal 
with sec-13 protein 8 (mLST8) has unknown functions. mTORC2 also shares mTOR, DEPTOR, mLST8, 
and Tti1/Tel2, but has the unique protein components rictor (rapamycin-insensitive companion of 
mTOR), mSin1 (mammalian stress-activated map kinase interacting protein 1), and protor 1/2 (protein 
observed with rictor 1 and 2) (Laplante and Sabatini 2012). 
 Rapamycin is a macrolide antifungal produced by Streptomyces Hygroscopius discovered on the 
island of Rapa Nui (Easter Island). Its anti-proliferative effects are mediated by inhibition of mTOR. 
Rapamycin binds to FKBP12 (12-kDa FK506-binding protein) and the complex inhibits mTORC1 
(Brown et al 1994, Sabatini et al 1994). Rapamycin primarily targets mTORC1 although mTORC2 can be 
affected following long exposures, presumably due to sequestration of mTOR during complex turnover 
(Sarbassov et al 2005). 
mTORC1 localizes to the lysosomal membrane in response to amino acids. Amino acids activate 
Rag GTPases which interact with raptor to bring the mTORC1 to the lysosomal membrane (Sancak et al 
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2008). At the lysosomal surface mTORC1 is exposed to and can be activated by Rheb. Thus, the presence 
of amino acids is required before any other upstream signal can activate mTORC1. 
 The effects of mTORC1 activity can be generally categorized as promoting anabolic processes 
(cell growth, energy consumption) and inhibiting catabolic processes (molecular breakdown, energy 
production). mTORC1 stimulates protein translation primarily through eukaryotic initiation factor 4E 
binding protein 1 (4E-BP1) and cell size through regulation of ribosomal protein S6 (S6). mTORC1 also 
regulates cholesterol synthesis by activating sterol regulatory-element binding proteins 1 and 2 (SREBP1 
and SREBP2) which increase expression of genes involved in cholesterol and other sterol synthesis or 
regulation. 
 mTORC1 increases cap-dependent protein translation through phosphorylation of 4E-BP1. 
Initiation faction eIF4E is a component of the complex which recruits the 40S ribosome to the 5’-cap of 
an mRNA in order to begin translation. 4E-BP1 binds to and inhibits eIF4E until it is phosphorylated by 
mTORC1. Following phosphorylation 4E-BP1dissociates from eIF4E and translation can proceed. 4E-
BP1 is phosphorylated in an ordered manner: first at Thr37 and Thr46, then at Thr70, and finally at Ser65. 
Ser65 and Thr70 are the only sites phosphorylated by mTORC1 (Gingras et al 2001). Either inhibiting the 
pathway through Rapamycin treatment or activating mTORC1 via TSC mutations does not cause global 
changes in protein synthesis; instead, changes in a subset of transcripts occurs (Bilanges et al 2007, 
Thoreen et al 2009, Yu et al 2009). 
 Eukaryotic ribosomes consist of two subunits: the small 40S subunit and the large 60S subunit; 
S6 is part of the small 40S subunit. Ribosome biosynthesis begins in the nucleolus where the ribosomal 
RNAs are synthesized. Many of the ribosomal proteins, including S6, are imported from the cytoplasm to 
associate with the newly formed ribosomal RNAs in the nucleolus (Reviewed in (Meyuhas 2015)). The 
pre-40S ribosomal complex is then exported out of the nucleus. There has been intense interest in S6 
because it was one of the first and still one of the few ribosomal proteins known to be regulated by 
phosphorylation (Gressner and Wool 1974, Kabat 1970). mTORC1 increases S6 phosphorylation by 
activating S6 kinase 1 (S6K1) and S6 kinase 2 (S6K2). In response to growth factors, ribosomal protein 
S6 is phosphorylated in five locations in an ordered manner. S6 is first phosphorylated at Ser236 then 
Ser235 by multiple kinases, including S6 kinase (S6K) activated by mTORC1, but also 90kDa ribosomal 
S6 kinases (RSK), downstream of ERK1/2. S6 is next phosphorylated at Ser240 and Ser244 by S6K, 
downstream of mTORC1, and lastly at Ser247 (Martin-Perez and Thomas 1983). 
Knock-out of S6K in Drosophila is semi-lethal and causes a reduction in size (Montagne et al 
1999). This phenotype is consistent with findings from TSC2 or TSC1 knock-out Drosophila, where loss 
of the negative regulators hamartin or tuberin results in enlarged cells (Tapon et al 2001). However, 
unlike Drosophila, two homologues of S6K exist in mammals: S6K1 and S6K2. S6K1 has two isoforms: 
p70 S6K1, which is cytoplasmic, and p85 S6K1, which is nuclear. Both isoforms of S6K2 are primarily 
nuclear. Originally S6K1 and S6K2 were thought to be redundant because in S6K-/- mice, S6K2 
expression is upregulated and S6 is still phosphorylated, suggesting compensation (Shima et al 1998). 
Surprisingly, loss of S6K1 and S6K2 have opposite effects on mouse body size; S6K1-/- mice are smaller 
while S6K2-/- mice are similar in size or even slightly larger. Double knock-out mice are pre- or 
postnatally lethal (Pende et al 2004). Interestingly, S6 mutant mice do not display prenatal lethality or 
smaller birth size, suggesting there are other S6K1 and S6K2 targets regulating prenatal development. S6 
also regulates glucose homeostasis, such that loss of S6K1 or mutations in S6 in mice display glucose 
intolerance similar to malnutrition during prenatal development (reviewed in (Meyuhas 2015)). Despite 
the fact that S6 is a critical component of the 40S ribosomal subunit, loss of phosphorylation of S6 does 
not alter global protein synthesis (Chauvin et al 2014, Garelick et al 2013, Mieulet et al 2007, Ruvinsky et 
al 2005). S6 is one of the essential early proteins involved in assembly of the pre-18S-rRNA prior to 
nuclear export and phosphorylation of S6 is critical to this process (Ferreira-Cerca et al 2005, Kruger et al 
2007, Zhang et al 2016). Rapamycin, inhibits S6 phosphorylation and causes accumulation of the pre-18s-
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rRNA in the nucleus, but it is not clear how over-activation of S6 would alter ribosomal assembly (Zhang 
et al 2016). 
 mTORC1 inhibits catabolic processes by regulating autophagy. mTORC1 phosphorylates ULK1 
and Atg13 which suppresses ULK1-Atg13-FIP200 complex activity, an early step in autophagosome 
formation (Ganley et al 2009, Hosokawa et al 2009, Jung et al 2009). The second mechanism connecting 
mTORC1 to autophagy regulation is through the transcription factor EB (TFEB). TFEB is the master 
controller activating autophagy genes, and it is regulated by its phosphorylation status. Phosphorylated 
TFEB localizes to the cytoplasm, unable to activate the autophagy gene network. Dephosphorylation of 
TFEB allows it to translocate to the nucleus (Sardiello et al 2009). mTORC1 phosphorylates TFEB, 
preventing activation of autophagy genes and lysosomal biogenesis (Martina et al 2012, Settembre et al 
2012). In this way mTORC1, localized to the lysosomal surface, connects lysosome content and nutrient 
status to lysosome biogenesis. 
 The regulation and downstream effects of mTORC2 are not as well studied as mTORC1. One of 
the main effects of mTORC2 activation is phosphorylation of Akt1 at Ser473, which then enhances Akt 
phosphorylation at Thr308 by PDK1 (Sarbassov et al 2005). Phosphorylated and activated Akt can 
phosphorylate and inhibit tuberin, activating mTORC1.  
To complicate the pathway, mTORC1 also participates in several inhibitory feedback loops. 
S6K1 inhibits PI3K/Akt signaling by phosphorylating and inhibiting IRS1, preventing its association with 
PI3K. Decreased signaling through PI3K and phospho-AktThr308 then inhibits mTORC1 activity 
(Harrington et al 2004). S6 kinase can inhibit mTORC2 activity by phosphorylating rictor, leading to 
decreased phospho-AktSer473 (Julien et al 2010). The signaling changes usually seen in TSC2 or TSC1 
knock-out models are increased mTORC1 activity and decreased mTORC2 activity. 
 
mTOR in stem cells 
 
Given the essential function of mTOR in regulating cell metabolism and growth, it is not 
surprising that mTOR signaling impacts stem cell reprogramming and growth. mTOR protein as well as 
phospho-Akt and phospho-S6 protein levels drop during the first two days of reprogramming before 
returning to baseline levels at Day 3 (He et al 2012, Wang et al 2013). Overexpression of mTOR or 
inhibition of mTORC1 activity throughout reprogramming impairs reprogramming (He et al 2012, Wang 
et al 2013). Further, knock-out or knock-down of TSC2 inhibits reprogramming efficiency (He et al 
2012). The four reprogramming factors inhibit mTORC1 leading to elevated autophagy which enhances 
reprogramming (Wang et al 2013, Wu et al 2015). This highlights the strict regulation of mTOR during 
reprogramming. 
mTOR activity is crucial to stem cell maintenance and development. Loss of mTOR in mice 
causes E5.5-E6.5 lethality due to defects in cell proliferation and mTOR knock-out embryonic stem cells 
are unable to grow in vitro (Gangloff et al 2004, Murakami et al 2004). Excess mTOR activity in murine 
hematopoietic and germline stem cells leads to abnormal proliferation, differentiation, and exhaustion of 
the stem cell pool (Chen et al 2008, Magri and Galli 2013, Sun et al 2010, Zhou et al 2009). Mouse and 
Drosophila models further support a role for hamartin and tuberin in neural stem cell maintenance and 
precocious neuronal differentiation (Bateman and McNeill 2004, Feliciano et al 2013, Magri et al 2011, 
Magri and Galli 2013, Way et al 2009).  
Studies are just beginning to address the role of hamartin/tuberin and excess mTOR signaling in 
the human neural stem cell population. Human embryonic stem cells with homozygous or heterozygous 
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mutations in TSC2 have impaired formation of post-mitotic neurons from neural progenitors (Costa et al 
2016). However, this is not correctable with rapamycin treatment, pointing to a need for an improved 
understanding of the mechanisms and timing of neurodevelopmental abnormalities. 
 
Crosstalk between p53 and TSC/mTOR 
 
Tumor suppressor protein p53 is a transcription factor important in the regulation of apoptosis, 
senescence and cell cycle progression in response to various stressors. At baseline, p53 has a short half-
life and overall levels in the cell are low, but following stress signals, such as DNA damage, nucleoside 
depletion and hypoxia, p53 protein is rapidly stabilized to control the cellular response (reviewed in 
(Marine et al 2006)). The primary mechanism for p53 stabilization is through inhibition of its primary 
inhibitor, MDM2. MDM2 is an E3 ligase which ubiquitinates p53, targeting it for degradation, and also 
binds to the transcriptional activation domain to block p53 function (Haupt et al 1997, Kubbutat et al 
1997). Upon stabilization, p53 is then able to translocate to the nucleus to activate its transcriptional 
program. The various stress signals modify p53 by phosphorylation, sumoylation, acetylation and 
methylation to activate specific transcriptional responses. Further, p53 negatively regulates its own 
response by increasing MDM2 transcription. In this way p53 controls the cellular response to stress 
signals, pushing the cell towards cell cycle arrest if the cell can be repaired or towards apoptosis if the cell 
cannot survive the stress. 
Given its role in protecting the genomic integrity of the cell, p53 has important functions in stem 
cell biology and stem cell reprogramming. Overexpression of p53 in MDM2 mutant mice causes 
embryonic lethality between implantation and E7.5 (Kubbutat et al 1997). In 2006, Shinya Yamanaka 
identified four factors sufficient for reprogramming adult human fibroblasts to induced pluripotent stem 
cells, although the efficiency of reprogramming was low (Takahashi and Yamanaka 2006). Shortly 
thereafter four papers published in Nature in 2009 identified p53 as a potential barrier to reprograming. 
Knocking-down, knocking-out, or inhibiting p53 through genetic or pharmacologic means was found to 
enhance reprograming (Hong et al 2009, Kawamura et al 2009, Li et al 2009, Marion et al 2009, Utikal et 
al 2009). On the flip side, elevated p53 levels were found to impair reprograming (Li et al 2009). 
Knocking down p53 during the reprogramming process enhances reprogramming by overcoming stress 
signals from DNA damage, however, permanent ablation of p53 allows reprogramming at the expense of 
genomic integrity (Li et al 2009, Marion et al 2009). When MDM4, a negative regulator of p53, is 
knocked out in neural progenitors the mice have cell cycle abnormalities in the neural progenitors and 
increased apoptosis in the post-mitotic neurons (Francoz et al 2006).  
Throughout development cells must carefully balance cell growth and proliferation with 
senescence or apoptosis. p53 acts as a hub for sensing cell stress including DNA damage, nucleoside 
depletion, and reactive oxygen species. mTOR is an important pathway for sensing nutrient and growth 
factor status. In order to efficiently coordinate all of these inputs to appropriately regulate cell cycle 
progression and proliferation, crosstalk exists between these two important pathways. The same upstream 
regulator, AMPK, activates p53 and inhibits mTORC1 in order to pause cell proliferation and growth 
(Figure 1.2). AMPK senses AMP/ATP ratios or low energy levels and programs the cell to conserve 
energy including activating autophagy and decreasing protein translation, notably through inhibition of 
mTORC1 via tuberin. AMPK activates p53 by acetylation and inhibition of the inhibitor MDM4 (He et al 
2014, Lee et al 2012). Additionally, p53 may participate in a positive feedback loop by increasing 
phosphorylation of AMPK to further activate the kinase (Feng et al 2005). 
Ribosomal proteins are translocated to the nucleus where they localize to the nucleolus for 
assembly with rRNAs. Ribosomal stress, due to DNA damage or transcriptional inhibition, causes 
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disruption of the nucleolus and inhibition of further ribosomal protein nuclear import leading to increased 
ribosomal protein levels in the nucleoplasm or cytoplasm (Boisvert and Lamond 2010). Binding of 
ribosomal proteins to MDM2 leads to inhibition of MDM2 and stabilization of p53 protein (Boulon et al 
2010). Fourteen ribosomal proteins have been shown to bind to and inhibit MDM2 to increase p53 (Kim 
et al 2014). Mutant phosphorylation-resistant S6 mice harboring an oncogenic KRAS mutation show 
increased stability of p53 protein in the nucleus, but it is not clear what effect increased phosphorylation 
of S6 would have on p53 levels (Khalaileh et al 2013). 
DNA damage and genotoxic stress can inhibit mTORC1 signaling through multiple regulators, 
many of which converge on the tuberin/hamartin complex. DNA damage inhibits mTORC1 activity in a 
p53-dependent manner (Budanov and Karin 2008, Feng et al 2005, Horton et al 2002). One pathway 
connecting p53 to mTORC1 is through expression of the proteins Sestrin1 and Sestrin2, which increase 
phosphorylation and activation of AMPK. Increased activation of AMPK, in turn, increases 
phosphorylation and activation of tuberin and inhibits mTORC1 (Budanov and Karin 2008, Feng et al 
2005). Further, TSC2 mRNA and protein levels increase in response to DNA damage in a p53-dependent 
manner (Feng et al 2005, Feng et al 2007). These results support a p53-dependent inhibition of mTORC1 
in response to DNA damage via a rapid (minutes-hours) activation of AMPK along with a slower (12-24 
hours) induction of TSC2 mRNA and protein. However, Akt and MAPK can also inhibit phospho-S6 
following DNA damage in an mTORC1-, p53-, and AMPK- independent manner (Cam et al 2014). 
 
 
Figure 1.2 p53 and mTOR crosstalk 
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Existing studies using cells with loss of TSC1 or TSC2, including TSC patient AML samples, 
found mTORC1 activation of p53 with increased apoptosis or senescence, but the mechanism connecting 
p53 to mTORC1 was unclear (Habib et al 2011, Lee et al 2007, Miceli et al 2012, Pai et al 2016, Wataya-
Kaneda et al 2001, Zhang et al 2003) While attempting to generate MEFs to model TSC, Zhang et al. 
observed that TSC2-/- MEFs did not grow well unless the cells were immortalized by also knocking-out 
p53 (Zhang et al 2003). This was the first evidence that there may be interactions between TSC and p53. 
Renal angiomyolipomas from TSC patients have elevated p53 levels compared to kidney tissue from 
control patients. This is in marked contrast to the renal cell carcinomas of the TSC-model Eker rat, 
pointing to species-specific differences and a potential explanation for why TSC patients do not develop 
carcinomas like the rat model (Habib et al 2011). Homozygous TSC1 mutant MEFs are more sensitive to 
cell death following glucose starvation and genotoxic agents and have marked elevation of p53 (Lee et al 
2007, Pai et al 2016). This increased sensitivity to genotoxic cell death may be secondary to elevated 
AMPK activity with decreased ATP stores. The cell death phenotype can be partially inhibited by 
knocking-down p53 (Lee et al 2007). However, the mTORC1-inhibitor rapamycin, despite inhibiting p53 
and phospho-p53 levels, has shown mixed results in its ability to inhibit cell death (Lee et al 2007, Pai et 
al 2016). Rapamycin decreases p53 transcript association with polysomes, suggesting that mTORC1 
regulates p53 through increased translation of p53 protein (Lee et al 2007). Another potential mechanism 
connecting mTORC1 to p53 is through the p53 positive regulator ARF. ARF binds and sequesters MDM2 
to stabilize and increase p53 protein levels. Knocking-down or knocking-out TSC1 in MEFs increases 
ARF protein levels through increased translation, which then increases p53 protein levels; this is 
correctable with rapamycin treatment (Miceli et al 2012). All of these studies are in homozygous TSC 
mutant cells, but heterozygous skin tissue from TSC patients have increased rates of apoptosis, suggesting 
that at least some of these same pathways may be altered in heterozygous mutant cells as well (Wataya-
Kaneda et al 2001). 
Mouse and Rat Models of TSC 
 
The Eker rat was unknowingly the first animal model of TSC. It was initially used as a model of 
hereditary renal cell carcinoma before the causative mutation in Tsc2 and connection to TSC was 
identified (Eker 1954, Yeung et al 1994). Evidence from the Eker rat supported the model of TSC as a 
tumor suppressor pathway; the Eker rat has a germline heterozygous mutation in Tsc2 and tumor 
formation is consistent with loss-of-heterozygosity or Knudson’s two-hit hypothesis. However, the Eker 
rat is predisposed to renal cell carcinoma as well as pituitary, splenic, and uterine tumors, while human 
TSC patients rarely develop cancer or even hamartomatous growths in the pituitary or spleen. Comparing 
the Tsc2-null renal cell carcinoma tissue in the Eker rat to the TSC2-null renal angiomyolipoma tissue in 
TSC patients reveals divergent signaling pathways. While renal cell carcinomas in the Eker rat have 
decreased levels of PTEN and p53, tissue samples from patient angiomyolipomas have increased 
expression of p53 and PTEN (Habib et al 2011). This highlights the differences between the Eker rat renal 
cell carcinoma and human renal hamartoma pathogenesis. Further, it suggests that additional mutations in 
cancer driving pathways may be necessary for carcinoma formation in TSC patients.  
Heterozygous Tsc2 Eker rats have impaired novel object exploration and social behavior but have 
improved episodic memory for the Morris water maze or radial maze (Waltereit et al 2006, Waltereit et al 
2011). Germline homozygous Tsc2 Eker mutant rats are embryonic lethal midgestation due to defects in 
neural tube closure (Rennebeck et al 1998). Germline homozygous TSC2 mutant mice are embryonic 
lethal at E9.5-12.5 due to hepatic hypoplasia or neural tube defects (Kobayashi et al 1999, Onda et al 
1999). Heterozygous loss of Tsc2 or Tsc1 in mice causes a subtle neurological phenotype with impaired 
spatial and fear learning, abnormal mother-pup interactions, decreased spine density and impaired axonal 
guidance (Ehninger et al 2008, Goorden et al 2007, Nie et al 2010, Tavazoie et al 2005). 
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Summary 
 
 TSC is a pediatric disorder which causes epilepsy and intellectual disability. Mutations in TSC1 
or TSC2 cause benign growths in multiple organs but the onset of hamartomas varies from prenatally 
(cortical tubers) to post-puberty (lung LAM). The differences in the timing of onset (and regression or 
lack thereof) point to differences in the tissue specific pathogenesis of TSC lesions. Evidence from human 
samples and clinical trials supports the critical role of increased mTORC1 activity in the symptoms of 
TSC. While mTORC1 inhibitors have been shown to be effective in treating some aspects of the disease 
(e.g. SEGA, AML, and LAM), reversal of growth is usually static and is restricted to the treatment period, 
pointing to the need for a better understanding of mechanisms controlling cell growth and differentiation 
(Bissler et al 2008, Cardamone et al 2014, Franz et al 2006, Franz 2013, Krueger et al 2013, McCormack 
et al 2011, Sasongko et al 2016). This limitation could be potentially overcome by treatment targeting the 
specific cell types relevant to the disease process at the initial onset of dysfunction and thereby provide 
lasting protection against developmental abnormalities. Although the current model in the field centers on 
excess mTORC1 activity as the critical mediator of the neurologic symptoms, it is unknown how 
increased mTORC1 activity alters neurodevelopment to induce cortical malformations. 
Furthermore, while some lesions have evidence of loss of heterozygosity (kidney AML, facial 
angiofibromas, SEGAs), the cortical tubers have little evidence of second mutations. This, along with 
evidence of abnormalities in the heterozygous “normal” cortical regions in patients, led the field to 
consider alternative hypotheses. First, haploinsufficiency could be contributing to the neurological 
phenotype. Differences in tissue sensitivity to loss of tuberin could render neurons, oligodendrocytes, or 
astrocytes more sensitive to loss of tuberin or hamartin, such that loss of only one copy is sufficient to 
alter neural dynamics. Second, non-cell autonomous mechanisms could be causing formation of tubers 
and disrupting neurodevelopment. Small numbers of cells with loss of heterozygosity (e.g. the giant cells 
within the tubers) could be secreting factors which disrupt neighboring neurodevelopment. Possibly, it is 
a combination of mechanisms. Heterozygous mutations in TSC1 or TSC2 may cause subtle (by 
pathological standards) but widespread changes in neuron, oligodendrocyte, and astrocyte function. In the 
setting of this background process, then loss-of-heterozygosity causes non-cell autonomous localized 
disruption of neural development leading to tuber formation. 
To explore how gene dosage alters signaling and cellular dynamics in TSC, we have used 
fibroblasts, stem cells, and neural progenitors harboring heterozygous and homozygous mutations in 
TSC2. Chapter II presents evidence for heterozygous loss of TSC2 altering p53 protein response in 
fibroblasts and stem cells, providing a potential explanation for the lack of cancer development in TSC 
patients. Chapter III explores how heterozygous TSC mutations alter stem cell behavior. Chapter IV uses 
heterozygous and homozygous TSC2 mutant iPSCs to model early neural development in TSC. Our 
results support a model of haploinsufficiency in TSC but do not exclude non-cell autonomous 
mechanisms. 
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CHAPTER II  
 
HETEROZYGOUS LOSS OF TSC2 ALTERS P53 SIGNALING AND HUMAN STEM 
CELL REPROGRAMMING 
 
Parts of this work were published under the same title in Human Molecular Genetics by Oxford 
University Press (Armstrong, Westlake, Snow, Cawthon, Armour, Bowman, Ess, 2017). 
Abstract 
 
Tuberous Sclerosis Complex (TSC) is a pediatric disorder of dysregulated growth and 
differentiation caused by loss of function mutations in either the TSC1 or TSC2 genes, which regulate 
mTOR kinase activity. We generated induced pluripotent stem cells using dermal fibroblasts obtained 
from patients with TSC to test the hypothesis that heterozygous loss of TSC2 alters neurodevelopment. 
During validation, we found that stem cells generated from TSC patients had a very high rate of 
integration of the reprograming plasmid containing an shRNA against TP53. Here we showed loss of one 
allele of TSC2 in human fibroblasts is sufficient to increase p53 levels and impair stem cell 
reprogramming. Increased p53 was also observed in TSC2 heterozygous and homozygous mutant human 
stem cells, suggesting that the interactions between TSC2 and p53 are consistent across cell types and 
gene dosage. These results support the contributions of TSC2 heterozygous mutant cells to the 
pathogenesis of TSC and the important role of p53 during reprogramming. 
 
Introduction 
 
As described in Chapter I, Tuberous Sclerosis Complex (TSC, OMIM #613254) is a genetic 
disorder of pediatric onset characterized by benign tumor growths (hamartomas) in multiple organ 
systems including the brain, kidney, heart, skin, and lungs (Sahin et al 2016). The most debilitating 
symptoms in TSC are a consequence of brain involvement, including a high rate of epilepsy, autism 
spectrum disorder, and learning disabilities (Sahin et al 2016). Emerging evidence discussed in Chapter I 
suggests that heterozygous mutations may contribute to the neural pathogenesis of TSC. We hypothesized 
that heterozygous loss of TSC2 would be sufficient to alter neural development in vitro in a stem cell 
model of TSC. However, in the process of generating stem cells to address these questions, we found a 
surprising role for heterozygous mutations in TSC2 in the regulation of p53 and the reprogramming 
process. 
We generated induced pluripotent stem cells (iPSCs) using human dermal fibroblasts obtained 
from TSC patients and control volunteers. We reprogrammed primary fibroblasts using established 
episomal methods employing three plasmids expressing OCT4, KLF4, SOX2, L-MYC, LIN28, and a 
shRNA knockdown targeted to TP53 (Okita et al 2011). Inhibiting mTORC1 or knocking out TSC2 
impairs reprogramming efficiency, suggesting that mTORC1 activity is tightly regulated during 
reprogramming (He et al 2012, Wang et al 2013). Knocking down p53 enhances reprogramming 
efficiency and survival; however, the mTOR pathway is also known to interact with p53. p53 inhibits 
mTORC1 signaling, notably upregulating TSC2, but the role of mTORC1 in the regulation of p53 is less 
clear (Budanov and Karin 2008, Cam et al 2014, Feng et al 2005, Feng et al 2007, Horton et al 2002, 
Stambolic et al 2001). Existing studies using cells with loss of TSC1 or TSC2, including TSC patient 
AML samples, found mTORC1 activation of p53 with increased apoptosis or senescence (Habib et al 
2011, Lee et al 2007, Miceli et al 2012, Pai et al 2016, Wataya-Kaneda et al 2001, Zhang et al 2003). As 
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most studies were done in the context of homozygous loss of TSC1 or TSC2, it is unclear how 
heterozygous loss of TSC2 in patient fibroblasts might affect p53 and stem cell reprogramming. We now 
show that loss of one copy of TSC2 is sufficient to increase p53 levels and inhibit reprogramming to 
iPSCs. These results indicate critical interactions between hamartin/tuberin, mTOR, and p53 to regulate 
stem cell reprogramming, cell maintenance, and cell death. 
 
Results 
 
TSC patient fibroblasts harbor heterozygous mutations leading to nonsense mediated decay of TSC2. 
 
To develop a human in vitro model of TSC, we derived primary dermal fibroblast cultures from 
multiple patients with TSC. The diagnosis of TSC was based on clinical presentation, genetic testing, and 
imaging studies (Table 1.2). Fibroblasts were isolated from patients’ normal-appearing skin or from TSC 
associated skin lesions Shagreen patches or hypopigmented macules, (also known as “Ash leaf spots”). 
The original intent, consistent with the two-hit hypothesis, was to acquire fibroblasts with either 
heterozygous or homozygous genetic mutations in TSC1 or TSC2; the reasoning being that normal 
appearing skin had a germline heterozygous mutation whereas TSC associated skin lesions also had a 
second somatic mutation. These Tuberous Sclerosis Patient (TSP) cells were later sequenced using highly 
redundant exome sequencing to identify pathogenic mutations in either TSC1 or TSC2. For all TSP lines, 
we identified only heterozygous mutations of either TSC1 or TSC2 regardless of whether the fibroblasts 
were obtained from normal appearing skin or skin lesions (E. Armour Dissertation, Vanderbilt 
University). Thirty-three percent of the tested lines contained no identifiable mutation in TSC1 or TSC2, 
broadly consistent with clinical testing for patients with TSC (Rosset et al 2017). As mutations in TSC2 
are more common than TSC1 and patients with mutations in TSC2 tend to have more severe disease 
(Dabora et al 2001, Devlin et al 2006, Jansen et al 2008a, Kothare et al 2014), we selected three well 
characterized patient lines with nonsense mutations in TSC2 (denoted as TSP20, TSP23, TSP31) (Table 
1.2). To determine whether the premature stop codon mutations lead to nonsense mediated decay of RNA 
transcripts, we sequenced mRNA from these patient lines. Only the wild-type mRNA was detectable by 
sequencing in TSP20, TSP23, and TSP31 fibroblast lines (Figure 2.1A). Consistent with these sequencing 
results, mRNA levels of TSC2 and expression of tuberin protein in TSC2 heterozygous mutant fibroblast 
lines were both reduced by approximately one-half compared to control fibroblasts (Figure 2.1B-C, 
p=0.039 and p=0.016). As tuberin is an important negative regulator of mTORC1 we next measured 
phospho-S6, a downstream target of mTORC1. We did not observe increased mTORC1 activity in 
fibroblasts with or without nutrient starvation (Figure 2.1D).  
 
Table 1.2: TSC Patients        
Patient Gene DNA 
NG_005895.1 
Protein 
NP_000539.2 
Exon Age of 
Epilepsy 
Onset 
Autism Intellect. 
Disability 
Age at 
dermal 
biopsy 
Biopsy site 
TSP20 TSC2 g.11900T>A p.Cys203Ter 6/41 6 months Y Y 6 years Hypopigmented 
patch 
TSP23 TSC2 g.34854C>T p.Arg1032Ter 26/41 6 months Y Y 2 years Hypopigmented 
patch 
TSP31 TSC2 g.40172C>T p.Gln1419Ter 33/41 2 months Y Y 12 years Shagreen Patch 
Table 1.2. TSC Patient Clinical History, Biopsy Information, and Genotyping  
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Figure 2.1. Heterozygous nonsense mutations in TSC2 result in reduced TSC2 mRNA and tuberin 
protein levels.  
(A) Sequencing confirms single nucleotide changes causes premature stop codons in TSC2+/- fibroblasts. 
DNA sequencing reveals wild type and mutant allele but only wild-type allele was detected in mRNA. 
(B) TSC1 and TSC2 mRNA quantified by qPCR in control and TSC patient (TSP) fibroblasts (n=3 
average of four experimental replicates; p=0.039, t-test). (C) Tuberin and hamartin protein quantified by 
immunoblot (n=3; p=0.016, t-test). (D) Control and TSC2+/- fibroblasts were grown in DMEM complete 
or DMEM without glucose for 5hrs. Protein levels of phospho-S6 were quantified by immunoblot (n=3). 
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Figure 2.2. Induced pluripotent stem cell validation.  
(A) Stem cell lines were stained for expression of several pluripotent markers (OCT4, SSEA3, SSEA4, 
NANOG, TRA-1-60) at 10X (CC-3, T23-1, T20-7) or 20x (CE-6, T31-21) magnification. (B) Stem cell 
lines were differentiated to embryoid bodies to confirm pluripotency with capacity to form all three germ 
layers (mesoderm, endoderm, and ectoderm) and then analyzed by a panel of qPCR primers directed at 
mRNA transcripts associated with each germ layer or pluripotency. 
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Selective retention of reprogramming plasmid with shRNA against TP53 
 
We next reprogrammed control (obtained from healthy unrelated volunteers) and TSP fibroblast 
lines to iPSCs by transfecting episomal plasmids expressing the reprogramming genes OCT4, KLF4, 
SOX2, L-MYC, LIN28, as well as a shRNA knockdown targeted to TP53 (Okita et al 2011). All TSP and 
control iPSC lines were validated as pluripotent both by expression of established stem cell markers and 
the ability to differentiate to all three germ layers (Figure 2.2). The reprogramming plasmids used are 
expected to remain episomal in the cytoplasm and then be lost from emerging iPSCs through the repeated 
cell division and passaging required for iPSC generation. As the original publication from the Yamanaka 
laboratory reported occasional genomic integration of the reprogramming plasmids (Okita et al 2011), all 
iPSC lines were checked for plasmid integration using a PCR assay. Although control lines showed the 
expected low rate of integration (20%) (Okita et al 2011, Schlaeger et al 2015), TSP lines showed a 
marked increase in the incidence of integration of one or more of the plasmids (80%, Figure 2.3A 
p=0.023). To determine whether this was consistent across multiple rounds of reprogramming, we also 
included several additional iPSC lines from controls and patients with TSC that were not as fully 
characterized. The high rate of plasmid retention was an unexpected finding that has not been observed 
while reprogramming any of the other genetic disorders modeled with iPSCs in our laboratory or those of 
collaborators (>100 independent iPSC lines made to date). In TSP lines, this could be explained by an 
increased tendency to integrate any exogenous DNA or may reflect a requirement for sustained 
expression from one or more of the plasmid-encoded genes to drive cellular proliferation and survival 
during the stress of reprogramming. To distinguish these possibilities, we designed PCR primer sequences 
to unambiguously identify each plasmid used for reprogramming. In the control integrated lines, one of 
the two integrated control lines integrated only the OCT4/shTP53 plasmid and the other had integrated 
more than one plasmid. In contrast, all of the TSP iPSC lines integrated only a single plasmid, the one 
that expresses both OCT4 and the shRNA directed against TP53 (Figure 2.3B).  
Studies from our group and others supporting a complex interaction between tuberin, mTOR, and 
p53 led us to hypothesize that p53 signaling would be altered in cells from patients with TSC (Habib et al 
2011, Lee et al 2007, Miceli et al 2012, Pai et al 2016, Wataya-Kaneda et al 2001, Zhang et al 2003). To 
determine whether the incorporated shRNA to TP53 was expressed and functioning, we measured p53 
protein levels in non-integrated control, integrated control, non-integrated TSP and integrated TSP iPSC 
lines. For the integrated TSP lines, p53 protein levels were decreased in 5 out 6 of the integrated TSC2+/- 
iPS lines measured (Chapter III Figure 3.1). Furthermore, integrated iPSCs displayed increased 
proliferation and survival following single-cell suspension, which is consistent with decreased p53 levels 
(Chapter III Figure 3.6). 
Given a recent report showing that human stem cells acquire mutations in p53 in culture, we 
further sequenced 16 identified “hot spots” in our original fibroblasts as well as several iPSC lines 
(Merkle et al 2017). We did not identify any mutations in p53 that might explain the increased rate of 
integration in the TSC patient lines. 
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Figure 2.3. Increased integration of reprogramming plasmids in TSP iPSC lines.  
(A) PCR for continued presence of the reprogramming plasmids at passage ≥10. Multiple iPSC clones 
generated from five individual patients and five individual controls were analyzed. Plasmid bands were 
detectable in eight of ten TSC2 heterozygous mutant clones analyzed and two of ten control clones from 
control volunteers (p=0.023, Fisher’s exact test). (B) PCR to distinguish between the three 
reprogramming plasmids. 
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Increased levels of p53 in TSC2 heterozygous mutant fibroblasts  
 
In normally growing “unstressed” cells, p53 is a transcription factor that is rapidly ubiquitinated 
by MDM2 and degraded. However, following DNA stress, p53 is stabilized in the nucleus where it 
regulates gene transcription. We examined p53 levels and found expression in both TSP and control 
fibroblasts were barely detectable by immunoblotting and immunofluorescence. We tested whether p53 
activity was increased in TSP fibroblasts after DNA damage. Control and heterozygous TSC patient 
fibroblasts were exposed to UV light, and twenty-four hours later nuclear p53 was measured by 
immunofluorescence. The mean fluorescent intensity of p53 was significantly higher in TSC2 
heterozygous mutant fibroblasts compared to controls (Figure 2.4A, p<0.01). To test whether the increase 
in p53 was due to increased mTORC1 activity, we treated fibroblasts with the mTORC1 inhibitor 
rapamycin beginning 24 hours before and continuing 24 hours after UV challenge. Rapamycin treatment 
at concentrations near the IC50 (0.2 nM) decreased nuclear p53 levels in both control and TSP cells 
(Figure 2.4A, p=0.008). With rapamycin treatment, the p53 signal decreased in both wildtype and TSP 
cells, and in TSP cells was reduced to the level of untreated control cells (Figure 2.4A). This pattern is 
consistent with an interaction between TSC2, mTORC1 and p53. 
To determine the impact of TSC2 heterozygous mutations on the response to DNA damage, p53 
levels in control and TSP fibroblasts were measured at 0, 8, 16, and 24 hours following UV challenge. 
p53 levels rapidly increased with TSP fibroblasts upregulating p53 significantly more relative to controls 
(Figure 2.4B, p=0.035, interaction). Tuberin protein levels were also significantly increased in response 
to UV challenge, consistent with previous studies (Figure 2.4B, p<0.0001, time) (Feng et al 2005, Feng et 
al 2007). However, the relative response was similar in both control and TSP fibroblasts, suggesting the 
wild-type copy of TSC2 is appropriately upregulated in TSC2 heterozygous mutant fibroblasts following 
UV exposure. To further assess p53 activity and function, we measured p21, a cyclin-dependent kinase 
inhibitor whose levels are regulated by p53. Levels of p21 increased post-UV challenge and TSP lines 
displayed increased p21 relative to controls (Figure 2.4B, p=0.01). mTORC1 signaling, as measured by 
phospho-S6 levels, showed a small initial increase at 8 hours before normalizing to pre-challenge levels; 
however, no difference between control and TSP lines was observed (Figure 2.4B). The activity of 
mTORC2, as measured by pAktSer473, decreased following UV challenge but there was, again, no 
difference between control and TSP fibroblasts for genotype (Figure 2.4B). Degradation of p53 protein is 
tightly regulated by ubiquitination by MDM2, which is activated by phosphorylation at serine residue 
166. There were no differences seen in pMDM2Ser166 levels and it was appropriately upregulated in 
response to increased p53 levels in both controls and TSP lines (Figure 2.4B). 
Phosphorylation of p53 at Ser15 by ATM, ATR and AMPK increases its stability and its activity 
(Loughery et al 2014). In order to measure phosphorylation of p53, it was necessary to enrich for nuclear 
protein extracts. Twenty-four hours post-UV challenge, nuclear and cytoplasmic extracts were isolated 
from control and heterozygous TSC2 fibroblasts. Although the results were not significant, the overall 
pattern of increased p53 protein in the nucleus of TSC2+/- fibroblasts was consistent with what was 
observed by immunofluorescence and whole-cell extract immunoblot (Figure 2.5A, p=0.247). There was 
no significant difference in nuclear phospho-p53 Ser15 normalized to p53 or nuclear pMDM2Ser166 (Figure 
2.5B-C). However, each individual line was measured over multiple experimental replicates and the 
direction of the change in TSC2+/- fibroblasts was consistent across all experimental replicates. 
Interestingly, while there was no difference in phospho-S6 Ser240/244 in whole cell extracts (Figure 2.4B), 
there was a significant increase in nuclear phospho-S6 Ser240/244 following UV challenge in heterozygous 
TSC2 fibroblasts (Figure 2.5D, p<0.05). However, future studies are necessary to rule out a possible 
contribution of lysosomes, mitochondria or other organelles which may be segregating with the nuclear 
extraction 
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Figure 2.4 TSC patient fibroblasts display increased p53 in response to UV light.  
(A) Three control and two TSC patient fibroblast lines were challenged with UV light and then 
immunostained for p53 24 hours later. Cells were treated with 0.2 nM rapamycin for 24 hours before and 
24 hours after UV challenge. Mean fluorescent intensity of p53 was quantified in nuclei defined by 
Hoechst staining. Nuclear p53 was analyzed by two-way ANOVA in UV treated cells (n=2-3; interaction 
p=0.532, genotype p=0.012, rapamycin treatment p=0.008; Bonferroni post-test control UV vs TSP UV 
p<0.01). (B) Fibroblast lines were exposed to UV light and protein isolated at 0, 8 16, and 24 hours post-
exposure was analyzed by immunoblot. (n=3, each patient average of 3-4 experimental replicates; two-
way ANOVA values in table). See also Figure 5.1 
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Figure 2.5. Changes in nuclear and cytoplasmic protein levels in TSC patient fibroblasts.  
Fibroblasts were challenged with UV light and protein was isolated from nuclear and cytoplasmic 
compartments 24 hours later. Phospho-p53 Ser15, phospho-MDM2 Ser166 and phospho-S6 Ser240/244 proteins 
were quantified by immunoblot. (A) Total p53 protein normalized to total protein (n=3, average of 3 
experimental replicates; interaction p=0.238, UV treatment p=0.001, genotype p=0.247, two-way 
ANOVA) (B) Phospho-p53 protein normalized to total p53 (n=3, average of 2 experimental replicates; 
p=0.146 t-test) (C) Phospho-MDM2 protein normalized to total protein (n=3, average of 2 experimental 
replicates; p=0.229 t-test) (D) Phospho-S6 normalized to total S6 (n=3, average of 2 experimental 
replicates; interaction p=0.088, UV treatment p=0.060, genotype p=0.135; Bonferroni post-test Control 
UV vs TSP UV p<0.05)  
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Impaired reprogramming and cell death in TSC2 heterozygous mutant cells 
 
p53 has been reported to be increased during cellular reprogramming, likely via the DNA damage 
pathway, and knocking down p53 enhances reprogramming efficiency (Hong et al 2009, Kawamura et al 
2009, Li et al 2009, Marion et al 2009, Okita et al 2011). We hypothesized that the increased p53 levels 
seen in TSC2 heterozygous mutant fibroblasts would impair reprogramming efficiency. To test this, we 
embarked on further rounds of reprograming using two control and three TSP fibroblast lines with either 
the same three programming plasmids used previously or by using the same genes except omitting the 
shRNA cassette directed against TP53. Three weeks following plasmid reprogramming, we stained the 
resulting iPSC colonies for alkaline phosphatase (AP) as a marker of pluripotency and quantified the 
number of positive AP colonies (Figure 2.6A). We expected the largest difference between controls and 
TSC2+/- cells to be in the lines reprogrammed without the shTP53 cassette; however, the reprogramming 
efficiency was too low in both groups to draw conclusions. We hypothesized that the addition of the 
shTP53 cassette would partially rescue the reprogramming efficiency of TSC2+/- fibroblasts, with the 
caveat that TSC2+/- lines would need to integrate the shTP53 plasmid and integration may be a rare 
event. Reprogramming efficiency was significantly reduced in TSC2 heterozygous mutant fibroblasts 
compared to controls reprogrammed with shTP53 (Figure 2.6A, p=0.015). However, there was no 
significant difference between reprogramming efficiency of TSC2+/- fibroblasts with or without the 
shTP53 cassette (Figure 2.6A). We found reprogramming efficiency correlated inversely with the 
expected p53 levels: the number of AP+ colonies was highest in control fibroblasts reprogrammed with 
the shTP53 and lowest in TSC2 heterozygous mutant fibroblasts reprogrammed without the shTP53 
plasmid. As AP is an early marker of pluripotency, we also picked and expanded several iPSC colonies 
from each experiment and stained them for the more mature stem cell marker TRA-1-60. We found TRA-
1-60 positive colonies from all control and TSP lines reprogrammed with or without shTP53.  
Given the known role for p53 in regulating apoptosis, we next hypothesized that increased p53 in 
our TSP fibroblasts would lead to an increased rate of apoptosis. We first measured apoptosis in 
fibroblasts by Annexin V staining twenty-four hours after UV challenge. We found a significant increase 
in the percentage of Annexin V positive apoptotic cells in TSP fibroblast lines (Figure 2.6B, p<0.05). To 
determine whether mTORC1 signaling contributes to this finding we next treated fibroblasts with 
rapamycin for a total of 48 hours, starting 24 hours before UV challenge and 24 hours after. There was a 
significant interaction between rapamycin treatment and genotype (Figure 2.6C, p=0.012). Rapamycin 
had divergent effects on apoptosis in control and TSP fibroblasts. While rapamycin significantly 
increased apoptosis in control fibroblasts, there was no change, or perhaps even decreased, apoptosis in 
TSP fibroblasts (Figure 2.6C, p<0.05). 
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Figure 2.6. Impaired reprogramming and increased apoptosis in TSC patient fibroblasts.  
(A) Control (CA, CC) and patient (T20, T31, T23) fibroblasts were reprogrammed with the three 
plasmids including either the Oct4 plasmid containing shRNA to TP53 or the Oct4 plasmid alone. 
Pluripotent colonies were stained for alkaline phosphatase. Alkaline phosphatase positive colonies were 
counted using grey scale images in ImageJ (n=2 controls and 3 patients, average of 1-2 wells per 
individual; p=0.015, t-test). (B) Fibroblast lines were challenged with UV light and apoptosis measured 
by Annexin V staining by flow cytometry. Annexin V versus propidium iodide is plotted for untreated 
and UV challenged fibroblasts; control (blue) and TSP (green) samples have been combined for display 
purposes. (n=3 controls and 2 TSP, average of 2 experimental replicates; interaction p=0.048, genotype 
p=0.189, UV treatment p=0.007; Bonferroni post-test control UV vs TSP UV p<0.05). (C) Fibroblasts 
were treated with 0.2 nM rapamycin or DMSO for a total of 48 hours, starting 24 hours before UV 
challenge and ending 24 hours after. Apoptosis was measured by Annexin V staining by flow cytometry. 
(n=3, average of 2 experimental replicates; interaction p=0.012, genotype p=0.678, rapamycin treatment 
p=0.032; Bonferroni post-test Control Vehicle vs Rapa p<0.05). 
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Possible mechanisms of increased levels of p53 in TSC2 heterozygous mutant cells 
 
We next sought to determine the molecular mechanism of increased p53 protein in TSC2 
heterozygous mutant fibroblasts. We first measured TP53 mRNA levels and found no increase in TP53 
mRNA at baseline (Figure 2.7A). We instead observed decreased TP53 mRNA in TSP cells following 
challenge with UV light (Figure 2.7A, p=0.025). As alternative splicing results in multiple TP53 isoforms 
(Marcel et al 2011), we designed primers for both the 3’ end (Figure 2.7A) and the 5’ end (Appendix 
Figure 5.2) of the full-length transcript and found similar results. As p53 is important in regulating 
multiple cell processes (including, DNA repair, apoptosis, cell cycle, and reactive oxygen species), we 
wondered whether the increase in p53 in the heterozygous TSC2 fibroblasts represented activation of a 
specific p53 process. Using the same mRNA samples from UV treated fibroblasts we measured thirteen 
p53 target genes that were validated in multiple genome-wide data sets (Fischer 2017). Although none 
were significantly increased or decreased, the transcript that had the largest change in TSC2+/- fibroblasts 
was GDF15 mRNA, a secreted member of the TGF-β superfamily previously shown to be increased in 
TSC2-/- hESC-derived neurons (Figure 2.7A, p=0.171) (Costa et al 2016). We next tested the stability of 
p53 protein by treating cells with the translation inhibitor cycloheximide. Fibroblasts were challenged 
with UV light 24 hours prior to treatment with cycloheximide and protein samples were taken before and 
after one hour of cycloheximide treatment. There was no difference in the relative protein remaining 
following treatment supporting a similar degradation rate of p53 protein in control and TSP fibroblasts 
(Figure 2.7C). Next, we used the protease inhibitor MG132 to inhibit degradation of p53 in order to 
isolate the contribution of translation to increased p53 protein levels. Control and TSP fibroblasts were 
treated with MG132 for four or eight hours post-UV challenge. There was no difference in p53 protein 
levels between patient and control fibroblasts (Figure 2.7D). To test whether p53 transcription/translation 
was increased at baseline in TSC2+/- cells we treated patient and control fibroblasts with MG132 for 6 
hours without UV challenge and found no difference (Figure 2.7D). MG132 strongly increases p53 
protein and we worried that a ceiling effect may be obscuring any differences between controls and 
TSC2+/-. To test this, we compared p53 protein with MG132 treatment alone to MG132 and UV 
challenge. The addition of UV challenge should further stimulate p53 activation pathways increasing p53 
protein above proteasome inhibition alone. There was a significant increase in p53 protein levels in cells 
challenged with UV light and MG132 compared to MG132 alone, suggesting that MG132 treatment alone 
is not leading to a ceiling effect (Figure 2.7D p=0.02). The results of Figure 2.7D imply that the 
mechanism is increased p53 stability because when both groups are treated with the proteasome inhibitor 
MG132, there is no difference between the groups. However, at 8 hours post UV challenge the difference 
between controls and TSC2+/- cells was not significant (Figure 2.4B). Further, we cannot rule out the 
possibility that treatment with MG132 and UV challenge is increasing p53 to maximum levels and a 
ceiling effect is causing the lack of difference between controls and TSC2+/- fibroblasts. Finally, the 
more direct measurement of p53 stability using cycloheximide treatment did not find increased stability in 
TSC2+/- fibroblasts. 
  
26 
 
 
 
 
 
 
 
 
Figure 2.7. Stability, mRNA and translation of p53 in TSC2+/- fibroblasts.  
(A) mRNA levels of TP53 in fibroblasts were measured by qPCR at baseline using primers directed to the 
3’ end of the gene. Samples were normalized to ACTIN and PGK1. (n=3, 4 technical replicates; p=0.334, 
t-test) (B) Fibroblasts were challenged with UV light. Levels of TP53 mRNA were measured twenty-four 
hours later by qPCR using primers directed to the 3’ end (n=3, 4 technical replicates; p=0.023, t-test) 
Levels of GDF15 mRNA (n=3, 4 technical replicates; p=0.171, t-test) (C) Fibroblasts were challenged 
with UV light and 15 hours later treated with the translation inhibitor cycloheximide (100 μM) for two 
hours. p53 protein levels were analyzed by immunoblot and normalized to p53 at time 0 for each 
individual (n=3). (D) Fibroblasts were treated with the proteasome inhibitor MG132 (1 μM) for 4 and 8 
hours after UV challenge and p53 protein was measured by immunoblot (n=3). Fibroblasts were treated 
with MG132 (1 μM) for 6 hours with or without UV challenge. p53 protein levels were analyzed by 
immunoblot (n=3; interaction p=0.75, UV p=0.02, Genotype p=0.64, two-way ANOVA). See also Figure 
5.2. 
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p53 is increased in TSC2 heterozygous and homozygous mutant iPSCs  
 
To confirm the interaction between tuberin and p53 was not limited to one cell type, we generated 
non-integrated TSC2 heterozygous iPSC lines using Sendai viruses and measured p53 protein levels. 
Multiple iPSC clones from three controls and three TSC patients were treated with the DNA damaging 
agent neocarzinostatin. One of the control patients (CC) appeared to have lower p53 protein in both iPSC 
clones compared to the other controls leading to increased variability in the controls. p53 was 
significantly elevated in TSC2 heterozygous mutant cells (Figure 2.8A, p=0.04). To further analyze the 
interaction between tuberin and p53, we also generated TSC2 homozygous mutant human iPSCs using 
CRISPR-Cas9 technology (Mandegar et al 2016). At baseline, p53 is significantly elevated in TSC2 
homozygous mutant iPSCs compared to isogenic control lines (Figure 2.8B, p=0.03). TSC2 homozygous 
mutant lines at baseline have unchanged phospho-S6, phospho-4E-BP1, and phospho-AktSer473 levels 
(Figure 2.8B). However, as iPSCs are maintained in mTeSR media that is nutrient-rich, these conditions 
likely do not reflect cell responses to changing stresses and metabolic demands. To address this point, we 
nutrient starved cells for 2.5 hours in DMEM without glucose or serum. Wildtype cells decreased 
mTORC1 signaling appropriately, reflecting a switch in cellular metabolism from anabolic to catabolic. 
In contrast, TSC2 homozygous cells appeared unable to inhibit mTORC1 signaling with pS6 levels 
remaining high (Figure 2.8C, p=0.0002) However, when cells were starved in media without amino acids 
(HBSS), which signal to mTORC1 through Rag GTPases rather than tuberin/hamartin (Sancak et al 
2008), both wildtype and TSC2 homozygous mutant cells appropriately inhibited mTORC1 signaling 
(Figure 2.8C).  
We were unable to find any change in p53 stability or translation/transcription in the 
heterozygous TSC2 fibroblasts. However, because the fibroblasts required UV challenge to induce the 
p53 response it was difficult to appropriately time the cycloheximide or MG132 treatment with the UV 
treatment to detect a difference. However, TSC2-/- iPSCs eliminate this issue because they have increased 
p53 protein at baseline. We again measured p53 stability by cycloheximide treatment but found no 
difference between isogenic controls and TSC2 homozygous iPSC lines (Figure 2.9A). Treatment with the 
protease inhibitor MG132 to isolate the contribution of transcription and translation to the p53 phenotype 
also did not reveal a difference between isogenic controls and TSC2 homozygous iPSC lines (Figure 
2.9B). Treatment of the iPSCs with the DNA damaging agent neocarzinostatin for 1-2 hours, increased 
p53 levels in both control and mutant lines. Homozygous mutant TSC2 iPSCs displayed increased p53 
levels relative to control lines (Figure 2.9C, p=0.04). 
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Figure 2.8. Increased p53 in heterozygous and homozygous TSC2 mutant stem cells.  
(A) Non-integrated iPSC lines generated from TSC2 heterozygous patient fibroblast lines treated with the 
DNA damaging agent neocarzinostatin for 1 hour show increased p53 relative to controls. (n=6, 1-3 
experimental repeats per sample; p=0.04 t-test) (B) Protein levels of p53 and mTORC1/mTORC2 related 
proteins were measured at baseline in homozygous knockout and control stem cells (n=14, 2 clones with 
7 experimental repeats; p=0.03 t-test). (C) Homozygous TSC2-/- and isogenic control stem cells were 
nutrient starved for 2.5 hours in DMEM without glucose or HBSS media. Protein levels of pS6 were 
elevated in TSC2-/- iPSCs following nutrient starvation. (n=4, 2 clones with 2 experimental repeats; 
p=0.0002 t-test) See also Figure 5.3. 
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Figure 2.9. Stability, translation and DNA damage response in isogenic TSC2-/- stem cells.  
(A) TSC2-/- and control iPSCs were treated with cycloheximide (100 μM) for 30-60 minutes and p53 was 
analyzed by immunoblot (n=4, 2 clones and 2 experimental replicates) (B) TSC2-/- and control iPSCs 
were treated with MG132 (1 μM) for 1-2 hours and p53 protein was analyzed by immunoblot (n=4, 2 
clones and 2 experimental replicates). (C) iPSCs were challenged with DNA damaging agent 
neocarzinostatin for 1-2 hours. p53 protein levels were analyzed by immunoblot (n=4, 2 clones and 2 
experimental replicates; interaction p=0.65, genotype p=0.039, treatment p=0.056 two-way ANOVA).  
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Discussion 
 
Our initial intent was to generate heterozygous and homozygous TSC2 mutant iPSCs from TSC 
patient fibroblasts to study the impact of gene dosage on somatic cell reprogramming and subsequent 
differentiation to various lineages impacted in TSC. This approach was designed to study the current 
favored “two hit” model of TSC where the initial genetic event is a germline mutation in either TSC1 or 
TSC2 followed by a second somatic mutation in the other allele of TSC1 or TSC2. This model predicts 
that normal appearing tissues in patients with TSC to be heterozygous whereas any TSC associated focal 
abnormalities including skin lesions to be due to homozygous mutations. Despite deep sequencing of 
multiple primary lines, we were unable to find any homozygous mutant fibroblasts; all lines studied had 
only heterozygous mutations of TSC2 and tuberin was clearly present albeit reduced. Consistent with 
genotyping results, no difference in mTORC1 signaling was observed in patient fibroblast cells. This 
suggests that homozygous fibroblasts do not survive during the transition to fibroblast culture or do not 
contribute significantly to hypopigmented macules or Shagreen patches. A recent publication reported 
that focal areas of hypopigmentation in patients with TSC result from loss of heterozygosity in 
melanocytes rather than fibroblasts (Cao et al 2017). 
 Unexpectedly, by reprogramming TSC2 patient derived fibroblasts to make iPSCs, we also found 
strong evidence for an important role for p53. This supports a model of TSC2 haploinsufficiency 
contributing to cell dysfunction and clinical manifestations. Previous reports support a connection 
between loss of TSC1 or TSC2 and increased p53, but the nature of this interaction remains unclear. 
Potential mechanisms include S6 kinase mediated phosphorylation and inhibition of MDM2, decreased 
Akt mediated phosphorylation and activation of MDM2, increased translation of MDM2-inhibitor ARF, 
or increased p53 translation or transcription (Goudarzi et al 2014, Lai et al 2010, Lee et al 2007, Miceli et 
al 2012, Ogawara et al 2002). The mTOR/p53 pathways may act together within a negative feedback loop 
where increased mTORC1 leads to increased p53 and sensitivity to DNA damage in proliferating cells. 
Completing this potential feedback loop, increased p53 activity in response to DNA damage or other 
cellular stress may inhibit mTORC1 to decrease the potential for excessive proliferation. Fibroblasts 
increase tuberin levels in response to DNA damaging agents; however, in the presence of a heterozygous 
mutation in TSC2, p53 levels increased above the usual response seen in control cells, suggesting that this 
critical feedback loop is disrupted. This may then contribute to one paradox seen in TSC, that despite 
having mutations in the mTORC1 pathway, cancer is very rarely seen. 
Interestingly, the mTORC1 inhibitor, rapamycin, had diverging effects on apoptosis in control 
and TSP fibroblasts. Apoptosis was significantly increased in control fibroblasts while apoptosis was 
unchanged or decreased in TSP fibroblasts. Although loss of TSC2 or TSC1 sensitizes cells to cell death 
(Habib et al 2011, Lee et al 2007, Miceli et al 2012, Pai et al 2016, Zhang et al 2003), the effect of 
rapamycin on apoptosis and p53 is more complicated and appears to be cell type specific (reviewed in 
(Castedo et al 2002)). Our results suggest that rapamycin sensitizes cells to apoptosis in wildtype 
fibroblasts but in the setting of heterozygous loss of TSC2, which already have increased apoptosis, there 
is no change with rapamycin treatment.  
The mTORC1 inhibitor, rapamycin, inhibited p53 accumulation following DNA damage, 
supporting an interaction between these two pathways. Although, no difference in mTORC1 signaling 
was observed in heterozygous fibroblasts at baseline, we did observe increased phospho-S6 in the nucleus 
following UV challenge. This suggests that differences in mTORC1 may be localized to subcellular 
compartments and require environmental/nutrient stresses. Following ribosomal stress and nucleolar 
breakdown, binding of ribosomal proteins to MDM2 leads to inhibition of MDM2 and stabilization of 
p53 protein (Boulon et al 2010). It is possible that heterozygous TSC2 fibroblasts have localized changes 
in mTORC1 signaling in the nucleus that is sufficient to alter ribosomal dynamics and inhibit MDM2. 
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 Tuberin and p53 may intersect in multiple ways; however, we did not find a significant increase 
in p53 stability, p53 transcription/translation, or TP53 mRNA levels in TSC2 heterozygous mutant cells. 
Some of these changes may simply be below the sensitivity of current methods of detection. As treatment 
with MG132 induces other stress pathways and TSC2 homozygous mutant cells in general appear to be 
more sensitive to ER stress via proteasome inhibition (Kang et al 2011), it is possible that these other 
functions are obscuring any difference in p53 transcription or translation between controls and TSC 
patient cells. In the future, translation can be measured more directly using polysome profiling or 
radioactive labeling of proteins. Interestingly, we observed a decrease in TP53 mRNA levels in TSC2 
heterozygous mutant fibroblasts compared to controls following UV exposure. There is conflicting 
evidence for p53 autoregulating its own transcription either positively or negatively (Benoit et al 2000, 
Deffie et al 1993, Ginsberg et al 1991, Hudson et al 1995). Our observation of inversely correlated 
patterns of TP53 mRNA and protein levels with heterozygous loss of TSC2 is most consistent with 
negative autoregulation.  
Relative levels of p53 during reprogramming tightly correlate with reprogramming efficiency; 
knocking down or knocking out p53 enhances formation of pluripotent colonies while activating p53 with 
the pharmacological agent Nutlin inhibits reprogramming (Hong et al 2009, Kawamura et al 2009). 
However, permanent loss of p53 enhances reprogramming at the expense of later genomic instability 
(Marion et al 2009). The addition of shRNA to TP53 to the episomal plasmids attempts to circumvent this 
issue by transiently knocking down p53 only during reprogramming. Then, with the expected loss of 
episomal plasmids during cell division, p53 levels are restored to normal levels following the 
reprogramming process. We found reprogramming efficiency correlated inversely with the theoretical 
levels of p53 in our fibroblasts, which was consistent with previous publications demonstrating increased 
reprogramming efficiency with knock-down or mutation of p53. However, the shRNA against p53 was 
not sufficient to completely rescue the TSC reprograming phenotype. We hypothesize that knock-down of 
p53 is required in TSC2+/- cells beyond the first few days of reprogramming. The percent of cells that 
have lost the plasmids increases from 32% by week 1 post-transfection to 72% by week 2 and finally 95% 
by week 3 (Okita et al 2011). If survival and reprogramming is impaired in cells that do not have 
continued knock-down of p53 and integration is a sufficiently rare event then this could account for the 
differences we see in heterozygous TSC2 fibroblasts. However, we have not ruled out p53-independent 
mechanisms of decreased reprogramming efficiency in TSC2+/- fibroblasts. The transition of fibroblasts 
from partially reprogrammed cell to stable stem cell is regulated by a complicated network of changes and 
there are p53-independent interactions between the reprogramming factors and mTORC1 (Wang et al 
2013, Wu et al 2015). Future studies will be necessary to dissect the contribution of TSC2 to each stage of 
reprogramming and stem cell maintenance. One previous study of integration in episomally 
reprogrammed iPSCs observed that even wildtype fibroblasts had an increased tendency to integrate the 
OCT4/shTP53 plasmid over the other two plasmids, likely due to a growth advantage conferred by 
continued inhibition of p53 (Schlaeger et al 2015). We hypothesize that a similar mechanism is occurring 
in heterozygous cells but at a higher rate due to increased p53 in TSC patient-derived cells. 
 While a circuitous route was required to finally generate them, we now report the first generation 
of isogenic iPSCs with homozygous knock-out of the TSC2 gene. Using CRISPR-Cas9 to generate 
isogenic lines, we were able to confirm that loss of tuberin leads to increased p53, both at baseline and in 
response to DNA damage. Further, we used a non-integrating Sendai viral method to reprogram 
heterozygous TSP fibroblasts to iPSCs. Using heterozygous TSP Sendai generated iPSCs, we were also 
able to confirm that the increased p53 seen in patient fibroblasts in response to DNA damage also applied 
to the pluripotent stem cell state.  
 Finally, our results suggest that loss of one copy of TSC2 is sufficient to alter the cellular 
response to DNA damage and stress during reprogramming. The increased apoptosis in TSP derived lines 
then may further explain why cancer is quite rare in TSC and why any malignant transformation is 
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usually associated with p53 deletion (Habib et al 2011, Hayashi et al 2012). We further speculate that the 
increased rate of apoptosis may clarify why neural cells with second hits are either very rare or 
undetectable in the cortical lesions, (tubers) of patients with TSC. p53 also affects neural stem cell 
differentiation and self-renewal (Jacobs et al 2006, Li et al 2016, Meletis et al 2006, Mendrysa et al 2011, 
Tedeschi and Di Giovanni 2009) and we further hypothesize that even small disruptions in p53 pathways, 
like those seen in our heterozygous cells, could alter neural development. Future studies will address 
regulation of cell death and neural development by gene dosage and non-cell-autonomous effects using 
control, heterozygous and now homozygous mutant TSC2 stem cell lines. 
 
Materials and Methods 
 
Statistics 
All statistical analyses were conducted using GraphPad PRISM. Individual patient fibroblast lines 
or iPSC clones are treated as independent n. All other experimental or technical replicates are considered 
not independent and are averaged to obtain the final value for each patient clone/line. Four isogenic 
clones (two TSC2+/+, two TSC2-/-) were generated using CRISPR-Cas9. For experiments involving 
isogenic lines, both experimental and clone replicates are considered independent repeats and are shown 
in the data. 
 
Cell Culture and Stem Cell Reprogramming 
Fibroblasts were isolated from control volunteers (male, age 24 years, CA; female, age 18 years, 
CC; male, age 25 years, CX) or TSC patients (female, ages 2-12 years, Table 1.2) from normal-appearing 
skin and TSC associated skin lesions (Shagreen patches or hypopigmented macules). Fibroblasts were 
cultured in DMEM with 10% FBS, 1% non-essential amino acids, and 1% pen-strep. 
Fibroblasts were reprogrammed by transfection of cells using the Neon system (Invitrogen) with 
plasmids expressing KLF4, SOX2, OCT4, L-MYC and LIN28 with or without shRNA to TP53 (Addgene 
#27076, 27077, 27078, 27080) according to previously published protocols (Okita et al 2011). Cells were 
switched to TeSR-E7 media (StemCell Technologies) 48 hours post-transfection. Three weeks post-
transfection, some cultures were stained for alkaline phosphatase expression following fixation with 2% 
paraformaldehyde (Millipore SCR004). Pluripotent colonies positive for alkaline phosphatase were 
quantified in ImageJ (ver1.50e) by analyzing greyscale images, setting a threshold for positive staining, 
and counting the number of colonies with area ≥2 pixels (Schindelin et al 2012). Concurrently colonies 
from parallel plates were picked and transferred to Matrigel treated plates and grown in mTeSR1 media 
(Corning; StemCell Technologies). Sendai reprogramming was performed using the CytoTune iPS 2.0 
Sendai Kit (ThermoFisher) in feeder-free conditions according to manufacturer’s instructions. Nascent 
stem cells were passed to Matrigel and grown in mTeSR after one week. 
 
Protein Stability and Translation 
For p53 stability and translation analyses, cells were treated with 100 μM cycloheximide (Sigma 
7698) or 1 μM MG132 (Millipore 474790). Appropriate doses were determined by in-cell Western assay 
to measure the dose at which puromycin incorporation into the nascent transcript was inhibited or p53 
was stabilized. 
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Sequencing 
Mutation screening of TSC fibroblast samples was performed using highly redundant exome 
sequencing in candidate genes. Genomic DNA was isolated and sheared; then exon-containing DNA was 
captured using SureSelect XT (Agilent). Next generation sequencing was done on an Illumina HiSeq2000 
(Solexa) through the Vanderbilt Genome Sciences Resource. Variants were submitted to the TSC2 Leiden 
Open Variant Database (http://www.LOVD.nl/TSC2). Confirmatory sequencing was performed on DNA 
or RNA isolated from fibroblast cultures using QuickExtract Buffer (epicentre) or Qiagen RNeasy or 
Invitrogen PureLink RNA kits. RNA was converted to cDNA using random hexamers and 
ThermoScientific Superscript First-Strand Synthesis Kit. PCR amplicons were isolated using QiaQuick 
PCR Purification Kit. 
 
Quantitative PCR 
RNA was isolated from fibroblast cultures as above and converted to cDNA. Quantitative PCR 
was performed using Life technologies SYBR Green Master Mix and run on a QuantStudio real-time 
qPCR machine through the Vanderbilt VANTAGE Core. Samples were run in duplicate or quadruplicate 
technical replicates and normalized to levels of ACTIN and PGK1. 
 
Stem Cell Validation 
Integration was assessed in cell lines after ≥10 passages post-reprogramming using primers for 
the WPRE and EBNA segments of the Yamanaka reprogramming plasmids.(Okita et al 2011) Primers 
immediately flanking the shTP53 segment were used to distinguish between the three plasmids; presence 
or absence of the shTP53 plasmid was determined based on the size of the amplified fragment. 
Pluripotency was assessed by the ability to differentiate to all three germline lineages using the 
hPSC Taqman Scorecard (ThermoFisher A15870). iPSCs were differentiated as embryoid bodies for one 
week in DMEM/F12 glutamax with 20% knockout serum replacement, non-essential amino acids and 55 
μM β-mercaptoethanol. RNA was then isolated and converted to cDNA using the High-capacity Reverse 
Transcription Kit (ThermoFisher 4374966). Samples were analyzed by qPCR on the Applied Biosystems 
7900HT through the Vanderbilt VANTAGE Core. 
Karyotype analysis was performed using standard techniques (Genetics Associates, Inc. 
Nashville, TN). 
 
Immunoblotting 
Protein was isolated by lysing and scraping cells in RIPA buffer plus protease inhibitor cocktails 
2 and 3 and phosphatase inhibitor cocktail (Sigma P5726, P0044, P8340). Samples were rotated for 30 
minutes at 4°C, sonicated and then run on 4-12% NuPAGE BisTris gels in MOPS buffer. Gels were 
transferred to PVDF membrane at 95V for 90 minutes using the Bio-Rad Mini Trans-Blot Cell. 
Membranes were incubated overnight in primary antibody diluted in 5% BSA. Membranes were then 
incubated for 1 hour at room temperature in secondary antibody and imaged on an Odyssey Li-Cor 
machine. Samples were normalized to actin or to total protein measured using Li-Cor REVERT stain. To 
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control for intra-experimental differences in antibody concentration and Odyssey machine settings, 
normalized values are expressed as a percentage of the controls before averaging experimental replicates. 
Nuclear-cytoplasmic extractions were performed using the NE-PER Kit according to 
manufacturer’s instructions (ThermoFisher 78833). 
 
Immunofluorescence 
Cells were fixed in 4% paraformaldehyde for 20 min at room temperature, followed by 3x 5-
minute PBS washes. For intracellular antibodies, cells were then permeabilized with 0.1% Triton in PBS 
for 20 minutes at room temperature and blocked in 0.1% Triton plus 5% normal goat serum for 1 hour at 
room temperature. For extracellular antibodies, cells were blocked in 5% normal goat serum for 1 hour at 
room temperature. Cells were then incubated in primary antibody rocking overnight at 4°C. Following 5x 
10-minute PBS washes, cells were incubated with secondary antibody for 3 hours at room temperature.  
Nuclear p53 was measured by immunofluorescence followed by analysis of images with ImageJ 
(Schindelin et al 2012). A nuclear mask was generated using Hoechst staining and mean fluorescent 
intensity of p53 was measured using the outlines. 
 
DNA Damage 
Primary fibroblasts were passed to 6 well plates at 100,000 cells per well or 96 well plates at 
5,000 cells per well. Plates were then exposed to ~24 J/m2 (30 seconds of UV light G51T8 bulb 4.9 Watts 
with wavelength 254 nm at a distance of approximately 0.706 meters). Analyses were conducted twenty-
four hours later unless otherwise noted. iPSC lines were treated with 50 ng/ml of neocarzinostatin for 1-2 
hours. Optimal neocarzinostatin doses were determined using a dose-response curve measured by in-cell 
Western assay for p53 response.  
 
Flow Cytometry 
Single cell suspensions of fibroblasts were obtained by trypsinizing adherent cells and collecting 
supernatant, followed by filtration through a 40 μm filter. Cells were then counted, stained with 5 μl 
Annexin V (AF488, ThermoScientific A1320) and 0.5 μl of 1 mg/ml propidium iodide (Sigma P4864) per 
105 cells and immediately analyzed by flow cytometry. Cells were gated to exclude debris and doublets. 
 
CRISPR 
Doxycycline-inducible Cas9 iPSCs were generated and donated by the Conklin lab (Mandegar et 
al 2016). Cells were treated with 2 μM doxycycline for 24 hours prior to lipofection with Alt-R 
crRNA:trRNA complexes (IDTDNA). Guide sequences were designed using the online Zhang Lab 
CRISPR Design Tool (Hsu et al 2013). Guide RNA mixed with lipofectamine (1.5 μl 3 μM 
crRNA:trRNA, 0.3 μl lipofectamine 3000, 48.2 μl Opti-MEM) was added to a 96 well plate coated in 
Matrigel. Doxycycline-treated cells were isolated with Accutase and 40,000 cells were then added to each 
well. Two days later cells were expanded to a 6 well plate for subsequent colony picking or DNA 
isolation for T7 endonuclease analysis.  
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CHAPTER III  
 
STEM CELL DYNAMICS AND SIGNALING IN PLASMID-INTEGRATED TSC2+/- 
IPSCS  
 
Abstract 
 
Functioning mTORC1 activity is critical for stem cell self-renewal and differentiation. However, 
it is unknown what effect heterozygous loss of TSC2 would have on the stem cell state, and, further, how 
integration of the OCT4/shTP53 plasmid would affect this phenotype. We hypothesized that the shRNA to 
p53 would be expressed and functioning leading to increased cell proliferation and survival but that 
heterozygous loss of TSC2 would not further alter stem cell dynamics. Using non-integrated and 
integrated controls and TSP plasmid-reprogrammed human iPSCs we measured cell proliferation and 
mTORC1 signaling. However, while we confirmed increased cell proliferation in integrated lines, we 
were surprised to find decreased pluripotent stability and increased MEK1/2 signaling. Further, these 
changes were observed in integrated TSP lines but not integrated controls, suggesting an interaction 
between decreased p53 and decreased TSC2 in the stem cell state. 
 
Introduction 
 
As described in previous chapters, TSC is a developmental disorder causing benign hamartomas 
in multiple organ systems. Several of the hamartomas, cortical tubers and cardiac rhabdomyomas, are 
detectable in TSC patients as early as 20 weeks of gestation suggesting an important role for hamartin and 
tuberin in early prenatal development (Muhler et al 2007, Northrup and Krueger 2013, Park et al 1997, 
Prabowo et al 2013, Tsai et al 2014). To better understand the impact of TSC2 loss on development, we 
generated induced pluripotent stem cells (iPSCs) using human dermal fibroblasts obtained from TSC 
patients and control volunteers. We reprogrammed primary fibroblasts using established episomal 
methods employing three plasmids expressing OCT4, KLF4, SOX2, L-MYC, LIN28, and a shRNA 
knockdown targeted to TP53 (Okita et al 2011). In Chapter II we showed that loss of one copy of TSC2 is 
sufficient to increase p53 levels and inhibit reprogramming to iPSCs. These results indicate critical 
interactions between hamartin/tuberin, mTOR, and p53 to regulate stem cell reprogramming, cell 
maintenance, and cell death. mTOR regulation is critical to stem cell biology; loss of mTOR prevents 
mouse embryonic stem cells from growing in vitro and excess mTOR activity leads to inhibition of self-
renewal and exhaustion of mouse hematopoietic stem cells (Chen et al 2008, Gangloff et al 2004, 
Murakami et al 2004). In human embryonic stem cells, treatment with the mTORC1 inhibitor rapamycin 
decreased expression of pluripotent proteins Nanog, Sox2 and Oct4 (Zhou et al 2009). Further, rapamycin 
treatment during embryoid body differentiation enhanced mesoderm/endoderm protein expression and 
decreased ectoderm protein expression (Zhou et al 2009). Large increases and decreases in mTORC1 
activity alters stem cell biology, but it is unclear what effect heterozygous mutations in TSC2 will have on 
human stem cells or how the mutations will interact with integration of the OCT4/shTP53 plasmid. We 
hypothesized that integration of the shRNA to p53 will decrease p53 protein leading to increased cell 
proliferation and survival, but this will affect both controls and TSP integrated lines. We confirmed 
increased cell proliferation and survival in integrated lines but, surprisingly, found evidence for an 
interaction between TSC2 mutations and knockdown of p53 in the maintenance of pluripotency. 
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Results 
 
 To model neurodevelopment in TSC we generated induced pluripotent stem cells from patient 
and control volunteer fibroblasts using reprogramming plasmids. The reprogramming plasmids are 
expected to remain episomal and not integrate into the transfected cell genome. The plasmids are unable 
to be replicated and they should be lost following reprogramming as the cells continue to divide. 
However, as there is a chance that the plasmids will become integrated into the genome, all iPSC lines 
were checked for continued presence of the plasmids by PCR. Control lines had the expected low rate of 
integration, consistent with previous publications. However, iPSC lines from TSC patients integrated the 
plasmids at a significantly higher rate (Chapter II, Figure 2.3). Interestingly, the only plasmid the TSC 
lines integrated was the OCT4/shTP53 plasmid. In the previous chapter we showed that TSP fibroblasts 
have increased p53 potentially driving selection of colonies integrating the shRNA to p53.   
First, we wanted to confirm that the integrated TSC2+/- iPS lines had decreased tuberin 
expression and that the integration event was not altering tuberin mRNA or protein. We did observe a 
significant decrease in TSC2 mRNA, however, the reduction in tuberin protein in integrated TSC2+/- 
iPSCs did not quite reach significance (Figure 3.1A p=0.004, 3.1B, p=0.06). One line, T21-3, was 
generated from fibroblasts with a frameshift mutation in TSC2 which should result in a stop codon eight 
amino acids later. However, this iPS line had no change in tuberin protein (106.7% controls) or mRNA 
(101.6% controls). The frameshift mutation likely causes formation of abnormal tuberin protein rather 
than nonsense mediated decay; as such, this line has been excluded from Figure 3.1.  
Although we did not find any differences in mTORC1 expression in fibroblasts with 
heterozygous loss of TSC2, we wondered whether the stem cell state would prove more sensitive to 
heterozygous loss of tuberin than the terminally differentiated fibroblasts. To measure mTORC1 activity 
we quantified phospho-S6 levels by immunoblot. Surprisingly, integrated TSC2+/- iPSC lines had 
decreased mTORC1 activity rather than increased (Figure 3.1C). Control integrated iPS lines also had 
decreased mTORC1 activity. These results suggest that although integration of the OCT4/shp53 does not 
alter tuberin protein or mRNA, it is inhibiting mTORC1 activity. 
If the TSC iPSCs are integrating the shp53 plasmid in order to overcome increased levels of p53 
protein, then we would expect that the plasmid would need to be integrated in such a way that the shRNA 
continues to be expressed. To determine whether the integrated shp53 was functioning, we measured p53 
protein levels in control and integrated TSP iPS lines. All but one (T8-22) of the integrated iPSC lines had 
decreased p53 protein levels compared to non-integrated controls, suggesting that the shRNA is still 
expressed in the integrated iPSC lines. Overall, p53 protein levels in integrated TSP lines averaged 65% 
of non-integrated controls; however, the difference did not reach significance because of the outlier T8-22 
(Figure 3.2A, p=0.11). A recent report showed that human stem cells acquire mutations in p53 in culture 
(Merkle et al 2017). We wondered whether the TSP outlier, T8-22, had acquired a mutation in p53 such 
that it continued to express p53 protein but in a mutated form, effectively circumventing the need for 
shTP53. To test this, we sequenced p53 in T8-22 at sixteen of the most common “hot spots” acquired in 
iPSC culture; however, we did not find evidence of any p53 mutations. 
In order to obtain non-integrated TSP iPSCs, we reprogrammed three fibroblast lines with 
heterozygous TSC2+/- mutations, T20, T23 and T31, using the Sendai viral method. In contrast to 
integrated plasmid-reprogrammed TSP iPSCs, p53 protein levels at baseline were unaltered in Sendai-
reprogrammed TSP iPSCs (Figure 3.2B and Chapter II Figure 2.8A). Sendai-reprogrammed iPSCs also 
had decreased tuberin protein but did not have any change in mTORC1 activity (Figure 3.3A-B). This 
supports the hypothesis that it is integration of the OCT4/shp53 plasmid causing decreased p53 protein in 
iPSCs. 
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Figure 3.1. Heterozygous nonsense mutations in TSC2 result in reduced TSC2 mRNA and tuberin 
protein levels in plasmid-reprogrammed iPSCs.  
(A) TSC1 and TSC2 mRNA quantified by qPCR in control and TSP iPSCs (n=2-4 average of four 
technical replicates; TSC2 mRNA interaction p=0.37, genotype p=0.004, integration p=0.88 two-way 
ANOVA) (B) Protein was isolated from plasmid-reprogrammed control and TSP iPSCs and analyzed by 
immunoblot  for tuberin protein (n=1-5, average of 2-3 experimental replicates; interaction p=0.67, 
genotype p=0.06, integration p=0.50 two-way ANOVA) (C) mTORC1 signaling measured by phospho-
S6Ser240/244 normalized to total S6 (n=1-6, average of 3-5 experimental replicates; interaction p=0.04, 
genotype p=0.10, integration p=0.008 two-way ANOVA) 
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Figure 3.2. p53 protein expression in integrated TSP iPSCs.  
(A) Protein was isolated from plasmid-reprogrammed control and TSP iPSCs and analyzed by 
immunoblot for p53 protein (n=1-6, average of 3-4 experimental replicates per clone; interaction p=0.43, 
genotype p=0.91, integration p=0.11) (B) Non-integrated iPSC lines generated from TSC2 heterozygous 
patient and controls were analyzed by immunoblot for p53 protein (n=6, average of 1-3 experimental 
replicates per clone) 
 
 
 
Figure 3.3. Heterozygous nonsense mutations in TSC2 result in reduced tuberin protein in Sendai-
reprogrammed iPSCs.  
(A) Protein was isolated from Sendai-reprogrammed control and TSP iPSCs and analyzed by immunoblot 
for tuberin protein (n=6, average of 1-3 experimental replicates; p=0.02 t-test) (B) mTORC1 signaling 
measured by phospho-S6Ser240/244 normalized to total S6 (n=6, average of 1-3 experimental replicates) 
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 We validated all iPSCs for the ability to form pluripotent colonies and differentiate to all three 
germ layers (Chapter II, Figure 2.2). Although we were able to find TSP iPSC colonies which stained 
positively for pluripotent markers, we observed that during routine culture TSP iPSCs were more difficult 
to maintain and tended to spontaneously differentiate at a higher rate than controls. To measure the rate of 
spontaneous differentiation, colonies from three non-integrated controls, one integrated control and five 
integrated TSP iPSCs were purified using mechanical dissociation. Following growth in culture all cells 
were dissociated and analyzed by flow cytometry for the pluripotent marker TRA-1-60. As expected, the 
majority of control cells were pluripotent stem cells (Figure 3.4). In contrast, the integrated heterozygous 
TSP iPSCs had significantly lower percentages of pluripotent stem cells compared to non-integrated 
controls (Figure 3.4 p=0.02). Interestingly, the one integrated control line CC2 did not show the dramatic 
decrease in TRA-1-60 staining seen in integrated TSP iPSCs. Although we have not directly measured 
pluripotent stability in the non-integrated Sendai lines, we have not noted any problems with spontaneous 
differentiation during routine maintenance and passage. This suggests that the increase in spontaneous 
differentiation seen in integrated TSP iPSCs is a result of the combination of decreased p53 and decreased 
tuberin.  
Figure 3.4. Decreased pluripotent stability in integrated TSP iPSC lines.  
Colonies from control and integrated TSP iPSC lines were isolated and passaged mechanically. Following 
expansion in culture cells were stained for the pluripotent marker TRA-1-60 and analyzed by flow 
cytometry. TSP iPSCs had fewer pluripotent cells than controls (n=3-5; p=0.02 t-test)  
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When we analyzed control and TSP iPSC colonies for expression of pluripotent markers we 
observed a number of Oct4 bright cells in TSP cultures (Figure 3.5). These cells were always located at 
the edge of or outside the colony, suggesting exit from the colony structure. When control iPSCs 
spontaneously differentiate, the differentiating cells migrating away from the colony do not express 
pluripotent markers. This suggests that the integrated TSP iPSCs not only have increased rates of 
spontaneous differentiation but also the differentiating cells are differentiating abnormally. The TSP 
iPSCs all integrated the reprogramming plasmid with the OCT4/shp53 genes, so the OCT4 gene on the 
reprogramming plasmid could be contributing to the Oct4-bright cells. However, we do not see any 
differences in Oct4 staining within the colony itself (Figure 3.5). Despite the increase in spontaneous 
differentiation, when cells were differentiated as embryoid bodies we did not observe any preference 
towards one lineage (Chapter II Figure 2.2). There was a slight tendency to maintain expression of 
pluripotent transcripts which is consistent with our observation of continued expression of Oct4 protein 
outside of the colony. 
During routine passaging of stem cells, we noticed that heterozygous TSC patient iPS cells were 
much more tolerant of single cell passaging than controls. To quantify this, we counted the cells and 
plated them at equal numbers. The following day the plates were fixed and quantified by nuclear Hoechst 
fluorescence by plate reader. Integrated TSC patient lines had 379% more cells survive single cell 
passaging on average compared to controls (Figure 3.6A, p=0.035). We hypothesized that the increase in 
cell number was due to either decreased cell death during single cell suspension or increased cell 
proliferation. To address these possibilities, we first measured cell doubling time to determine whether 
increased proliferation. Control and integrated TSC2+/- iPSCs were plated into replicate 96 well plates 
and cell counts were obtained over four days.  Integrated TSC2+/- iPSCs had increased cell numbers over 
four days and decreased cell doubling time compared to controls (Figure 3.6B, p=0.008). Next, we 
measured cell death in cells grown overnight in adherent conditions or single cell suspension culture. The 
following day, cells were stained with Annexin V and Propidium Iodide to detect apoptotic and dead 
cells, respectively (Figure 3.6C). Although not significant, integrated heterozygous TSC2+/- cells had a 
small increase in Propidium Iodide negative (live and early apoptotic) cells compared to controls (Figure 
3.6C p=0.318), so we can’t rule out the possibility that increased cell survival in single-cell suspension 
contributes to the phenotype. 
ERK1/2 phosphorylation of tuberin inhibits the TSC complex and activates Rheb/mTORC1. 
ERK-mediated inhibition of tuberin has been proposed as potential pseudo-second hit in TSC tubers 
which have heterozygous mutations in TSC2 (Ma et al 2005). Integrated TSP iPSCs had increased 
MEK1/2 signaling, measured by phospho-ERK1/2, compared to control iPSCs (Figure 3.7A p=0.045). As 
TSP iPSCs consist of a mix of pluripotent colonies and spontaneously differentiating cells, we wondered 
whether the difference in signaling was a reflection of the differences in cell types in culture. To isolate 
signaling in the pluripotent cells we measured phosphoERK1/2 in TRA-1-60 positive cells by flow 
cytometry. An increase in the mean fluorescent signal of phospho-ERK1/2 was confirmed in two out the 
three TSP lines (Figure 3.7B). 
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Figure 3.5. Abnormal spontaneous differentiation in TSP iPSCs  
Colonies from control and integrated TSP iPSC lines were stained for the pluripotent markers TRA-1-60 
and OCT4 and analyzed by immunofluorescence.  
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Figure 3.6 Integrated TSC2+/- iPSCs have increased cell survival and proliferation  
(A) Control and TSC2+/- iPS cells were passaged as single cells to 96 well plates. Cell number was 
quantified by nuclear stain Hoechst fluorescence by plate reader (n=4-5 individual lines, average of 2-4 
experimental replicates per line; p=0.035 t-test). (B) Control and integrated TSC2+/- cells were counted 
and plated into 96 well plates. One plate was fixed every twenty-four hours and cell counts were 
measured by fluorescence of the nuclear stain Hoechst by plate reader. (n=4-5 individual lines, average of 
2-4 experimental replicates; p=0.008) (C) Control and integrated TSC2+/- iPSCs were grown in adherent 
or suspension culture for 21 hours without rock inhibitor. Cell death was measured by Annexin V and 
Propidium Iodide staining by flow cytometry. (n=2 controls and 3 TSP, p=0.318 t-test PI negative) 
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Figure 3.7 Increased MEK1/2 signaling in integrated TSC2+/- iPSCs  
(A) Protein was isolated from control and TSP iPSCs and analyzed by immunoblot for expression of 
phospho-ERK1/2. Phosphorylated protein was normalized to total ERK1/2 (n=4-5 individual lines; 
average of 2-4 experimental replicates; p=0.045 t-test) (B) Control and integrated stem cells were 
analyzed by flow cytometry. Following gating for TRA-1-60 positive pluripotent cells, the fluorescent 
intensity of phospho-ERK1/2 was analyzed.  
 
Discussion 
 
 We have generated integrated plasmid-reprogrammed as well as non-integrated Sendai-
reprogrammed iPSCs to explore the contribution of tuberin and p53 to stem cell maintenance. We initially 
sought to model early neural development in TSC using iPSCs generated from heterozygous TSC2+/- 
patient fibroblasts. However, in the process of generating TSC and control stem cells we discovered an 
important contribution of TSC2 to the reprogramming process, such that most of the TSP patient lines had 
integrated the OCT4/shp53 plasmid. This was further explored in Chapter II, where we showed that 
TSC2+/- fibroblasts have elevated levels of p53 protein following cell stress. We hypothesized that the 
TSC2+/- clones with continued expression of the shRNA to p53 would overcome the elevated p53 levels 
to proliferate and survive the reprogramming process. To test whether the shp53 is functioning and 
expressed in the integrated iPSCs we measured p53 protein levels by immunoblot. The integrated 
plasmid-reprogrammed iPSCs have reduced p53 protein; this is in contrast to the non-integrated Sendai 
reprogrammed lines which have normal (or elevated following DNA damage) p53 protein levels.  
In chapter II, we saw that tuberin protein levels rose in response to UV challenge. Previous 
studies have shown that p53 binds to and upregulates TSC2 mRNA and protein (Feng et al 2005, Feng et 
al 2007). We wondered whether continued expression of the shRNA to p53 would alter TSC2 mRNA or 
tuberin protein levels. However, we showed that integration of the OCT4/shp53 plasmid does not alter 
tuberin protein or mRNA expression; heterozygous TSC2+/- stem cells have similarly decreased TSC2 
protein in both the integrated plasmid-reprogrammed lines and the Sendai-reprogrammed lines.  
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Surprisingly, we observed decreased mTORC1 signaling measured by phospho-S6Ser240/244 in both 
the control and TSP integrated lines. This suggests that it is the integration causing decreased mTORC1 
signaling. There is evidence for p53 participating in a negative feedback loop to inhibit mTORC1 
(Agarwal et al 2016), so we hypothesized that continued expression of the shRNA to p53 would release 
this feedback loop and lead to increased mTORC1 in integrated lines. However, we observed the opposite 
result in the integrated iPSCs, suggesting there are other interactions that we have not explored. 
 The integrated TSP iPSCs, but not the control integrated iPSCs, have elevated phospho-ERK1/2. 
This finding is especially interesting as ERK1/2 phosphorylates and inhibits tuberin; elevated phospho-
ERK1/2 observed in tubers has been proposed as potential molecular “second-hit” to inhibit the remaining 
tuberin protein. Our findings are consistent with these previous studies. However, more studies are 
needed to determine whether the increase in phospho-ERK1/2 is due to heterozygous loss of TSC2 alone 
or whether it requires p53 knock-down as well. Future studies examining ERK1/2 signaling in the non-
integrated Sendai lines will further clarify this potentially interesting interaction. 
During routine maintenance of the integrated TSP stem cells, we observed increased spontaneous 
differentiation and increased cell number following single cell passage. Our results suggest that increased 
cell proliferation and increased cell survival in suspension underlie our observation of increased cell 
number following routine passaging. The time point chosen for the cell suspension experiment was likely 
too long as most cells in either control or TSC patient groups had died. However, these results are 
consistent with previous results in our lab (E. Armour Dissertation, Vanderbilt University) describing 
increased recovery of pluripotency markers in integrated TSC iPSCs following single-cell passage. We 
also observed increased cell survival and proliferation in our integrated control lines suggesting that 
integration of the OCT4/shp53 plasmid is causative in these phenotypes. Indeed, p53 is an important cell 
cycle and apoptotic regulator, such that loss of p53 would be expected to decrease cell doubling time and 
decrease cell death following single cell suspension. However, mTORC1 has also been shown to regulate 
cyclins and we have not formally ruled out a potential contribution of heterozygous loss of TSC2 to the 
increased proliferation in these lines. 
In contrast to the cell proliferation and survival phenotypes, the integrated control line CC2 did 
not display decreased pluripotent stability, suggesting that heterozygous loss of TSC2 is contributing to 
increased differentiation. Further, decreased p53 protein, in addition to increasing survival and 
proliferation, has been proposed to enhance reprogramming by increasing expression pluripotent genes, 
so it is unlikely to be responsible for the pluripotent instability in integrated TSP iPSCs. This is an 
interesting finding which will require further exploration in the non-integrated Sendai iPSC lines. 
We have shown that integration of the OCT/shp53 plasmid and heterozygous loss of TSC2 
interact in several ways which contribute to our understanding of how the p53 and mTOR pathway 
function in stem cells. Future studies will use non-integrated heterozygous iPSCs to more fully dissect 
these intriguing pathways. 
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Materials and Methods 
 
Statistics 
All statistical analyses were conducted using GraphPad PRISM. Individual patient-derived iPSC 
clones are treated as independent n. All other experimental or technical replicates are considered not 
independent and are averaged to obtain the final value for each patient clone/line. 
Cell Proliferation 
 Control and TSC2+/- iPSC cells were detached using Accutase, resuspended in mTeSR media 
with ROCK inhibitor and then plated in mTeSR at a concentration of 5X 103 cells per 96 well. A standard 
curve from 1.6E5 to 2.5E3 was prepared at the same time. Plates were fixed every twenty-four hours for 
four days in 4% paraformaldehyde and stained with nuclear marker Hoechst.  Black well plates were then 
read on a BIO-TEK Synergy HT Microtiter Platereader. Cell survival was estimated based on Day 0 cell 
numbers. Doubling time was calculated using exponential growth equation (least squares fit, weighted by 
1/Y2) in GraphPad Prism. Doubling times >72 hours were interpreted as not proliferating and were 
excluded from analysis. 
Flow cytometry 
iPSCs were isolated as single cells by enzymatic Accutase treatment and resuspended in 2.5% 
normal goat serum in PBS on ice. For surface TRA-1-60 staining, no cell permeabilization was used. 
Cells were filtered through a 40 μm filter and counted. Cells were then stained with 10µl/test TRA-1-60 
antibody (BD Biosciences #560193) or equivalent concentration of PE IgM isotype control. 
For measurements of detachment-triggered apoptosis, cells were grown in adherent cultures on 
Matrigel in mTeSR or in low adherence plates without rock inhibitor. Cells were stained with 5 μl 
Annexin V (AF488, ThermoScientific A1320) and 0.5 μl of 1 mg/ml propidium iodide (Sigma P4864) per 
105 cells and immediately analyzed by flow cytometry. Cells were gated to exclude debris and doublets. 
Immunofluorescence 
Cells were fixed in 4% paraformaldehyde for 20 min at room temperature, followed by 3x 5-
minute PBS washes. For intracellular antibodies, cells were then permeabilized with 0.1% Triton in PBS 
for 20 minutes at room temperature and blocked in 0.1% Triton plus 5% normal goat serum for 1 hour at 
room temperature. For extracellular antibodies, cells were blocked in 5% normal goat serum for 1 hour at 
room temperature. Cells were then incubated in primary antibody rocking overnight at 4°C. Following 5x 
10-minute PBS washes, cells were incubated with secondary antibody for 3 hours at room temperature.  
Immunoblotting 
Protein was isolated by lysing and scraping cells in RIPA buffer plus protease inhibitor cocktails 
2 and 3 and phosphatase inhibitor cocktail (Sigma P5726, P0044, P8340). Samples were rotated for 30 
minutes at 4°C, sonicated and then run on 4-12% NuPAGE BisTris gels in MOPS buffer. Gels were 
transferred to PVDF membrane at 95V for 90 minutes using the Bio-Rad Mini Trans-Blot Cell. 
Membranes were incubated overnight in primary antibody diluted in 5% BSA. Membranes were then 
incubated for 1 hour at room temperature in secondary antibody and imaged on an Odyssey Li-Cor 
machine. Samples were normalized to actin or total protein levels using Li-Cor REVERT stain. To 
control for intra-experimental differences in antibody concentration and Odyssey machine settings, 
normalized values are expressed as a percentage of the controls before averaging experimental replicates.  
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CHAPTER IV  
 
HOMOZYGOUS LOSS OF TSC2 CAUSES IMPAIRED MTOR REGULATION DURING 
NEURODEVELOPMENT 
 
Abstract 
  
 Tuberous Sclerosis Complex causes refractory epilepsy and intellectual disability but the 
pathogenesis of the neurological symptoms is not understood. Identifying when and in what cell types 
mutations in TSC1 or TSC2 lead to neurological dysfunction is the first step to better and more targeted 
treatments. Induced pluripotent stem cells provide the opportunity to study these processes in human 
model of neurodevelopment. We hypothesized that heterozygous and homozygous loss of TSC2 would 
lead to dysregulation of mTOR signaling in neural progenitors and impair neural differentiation. Here we 
show that homozygous loss of TSC2 leads to increased mTORC1 in neural progenitors and decreased 
neural progenitor formation. Future studies will be necessary to explore how heterozygous loss of TSC2 
alters neural differentiation in non-integrated iPSCs. 
 
Introduction 
 
The most debilitating symptoms of TSC are a consequence of brain involvement. Patients 
frequently have intellectual disability and refractory epilepsy. mTORC1 inhibitors have been used to 
effectively treat some of the hamartomatous growths in TSC; however, the effect is limited to the 
treatment period (Bissler et al 2008, Cardamone et al 2014, Franz et al 2006, McCormack et al 2011, 
Sasongko et al 2016). While mTORC1 inhibitors have a clear cytostatic effect both in vitro and in vivo, it 
is not known how effective they will be in treating symptoms not directly related to expanding 
hamartomas. Studies are underway to determine whether mTORC1 inhibitors are effective in treating 
epilepsy and cognitive symptoms, however a better understanding of the developmental impact of TSC1 
and TSC2 mutations could lead to more impactful treatment targeted to a specific time point and cell type. 
As mTORC1 activity is important in maintaining proliferating pluripotent cells, we hypothesized that 
mTORC1 activity would decrease during directed differentiation in wild-type cells and that TSC lines 
would be unable to inhibit mTORC1 activity during this period. Increased mTORC1 activity in other 
stem cell populations (hematopoietic, germline) causes increased differentiation and stem cell exhaustion 
(Chen et al 2008, Magri and Galli 2013, Sun et al 2010, Zhou et al 2009) and we hypothesized that the 
same would be true of neural stem cells with homozygous mutations in TSC2. 
To better understand the impact of heterozygous and homozygous TSC2 loss on 
neurodevelopment, we used heterozygous induced pluripotent stem cells (iPSCs) generated from patient 
fibroblasts using plasmid-reprogramming methods and isogenic homozygous TSC2-/- iPSCs generated 
using CRISPR-Cas9 techniques to edit the genome. Here we show that homozygous TSC2 stem cells are 
unable to regulate mTORC1 and mTORC2 activity during neural differentiation and, further, 
homozygous mutations in TSC2 impair formation of neural progenitors. 
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Results 
 
To determine how heterozygous loss of TSC2 alters early neural differentiation we differentiated 
non-integrated control and integrated TSC line TSP16-11 to neural progenitors. No mutation was 
identified in TSC patient TSP16 by exome sequencing of TSC1 or TSC2 (E. Armour Dissertation, 
Vanderbilt University). However, the patient meets the clinical criteria of TSC. Further, clone TSP16-8 
had decreased TSC2 mRNA levels and protein levels, although the variability in the control protein levels 
makes it difficult to draw any conclusions (Figure 4.1A-B). This suggests that the cells had a large 
deletion in TSC2 that would be missed by exome sequencing. Stem cells were differentiated to neural 
progenitors using a dual-SMAD inhibition protocol in adherent cultures (neural differentiation protocol 
#1) for 7 days. Cells isolated from day 0, day 3, day 5, and day 7 of neural differentiation were analyzed 
by flow cytometry. Forward-scatter and side-scatter are broad measurements of cell size and cell 
complexity, respectively. Based on the forward-scatter and side-scatter measurements, there are dramatic 
changes over the course of differentiation. On day 3, there is an initial increase in side-scatter or cell 
complexity (Figure 4.2). This may reflect the cellular response to the growth factors and small molecule 
inhibitors added to the media to induce differentiation. The sudden switch from pluripotency to neural 
differentiation involves a switch in transcription programs likely leading to increased cellular proteins. 
After this initial burst of cellular complexity, the side-scatter values decrease slightly, although they never 
return to the levels of day 0 cells (Figure 4.2). The forward-scatter showed that the cell size shrinks below 
their starting point by day 5 and day 7 (Figure 4.2). These patterns are similar in both control and TSP 
lines. 
To study the timing of cellular transition from pluripotent stem cell to neural progenitor we 
stained cells for the pluripotent marker Oct4 and the neural progenitor marker Pax6 and analyzed cells by 
flow cytometry (Figure 4.2). As expected, the pluripotent marker Oct4 is rapidly lost and by day 5 no 
Oct4 positive pluripotent stem cells were detected in the control line. At the same time, the control cells 
begin turning on Pax6 expression; by day 5 37% of the cells are positive and 78% are positive by day 7. 
In contrast, the integrated TSP line T16-11 appropriately downregulated Oct4 but did not upregulate Pax6 
signal. 
 
Figure 4.1 TSC2 mRNA and protein expression in TSP16-8 
(A) TSC1 and TSC2 mRNA quantified by qPCR in control and TSP16-8 iPSCs. (B) TSC2 protein 
quantified by immunoblot in control and TSP16-8 iPSCs. 
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Figure 4.2. Impaired formation of neural progenitors in integrated TSC iPSC line TSP16-11  
Control line CA6 and TSC line TSP16-11 were differentiated to neural progenitors using dual-SMAD 
inhibition in adherent cultures. Cells were isolated on Day 0, 3, 5, and 7 of neural differentiation and 
analyzed by flow cytometry. (A) Forward- and side-scatter show that both the control line and TSP line 
undergo similar changes in cell size and complexity during the first week of directed differentiation. (B) 
Both control and TSP lines downregulate pluripotency marker Oct4 during directed differentiation. TSP 
line TSP16-11 fails to upregulate neural progenitor marker Pax6. 
  
CA6 T16-11 
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To test the contribution of mTORC1 to neural differentiation, we treated cells with the mTORC1 
inhibitor rapamycin and analyzed cells by immunoblot. As was observed by flow cytometry, Pax6 levels 
were lower in TSP16-11 patient cells (Figure 4.3C genotype p=0.0003, post-test p<0.01). Although 
rapamycin inhibited mTORC1 markers phospho-S6 and phospho-4E-BP1 levels to 44-69% of normal 
(Figure 4.3A-B, p<0.0001 and p=0.006), treatment failed to increase Pax6 protein levels in the TSP16-11 
patient cells (Figure 4.3C).  
 
Figure 4.3 Impaired formation of neural progenitors in integrated TSC iPSC line TSP16-11 is 
mTORC1-independent  
Control iPSC line CA6 and TSP line TSP16-11 were differentiated to neural progenitors with or without 
20 nM rapamycin treatment. Protein was isolated on day 7 and analyzed for phospho-S6, phospho-4E-
BP1 and Pax6 levels. (A) Phospho-S6 protein normalized to total S6 (n=3 replicate wells; interaction 
p=0.05, genotype p=0.226, rapamycin p<0.0001) (B) Phospho-4E-BP1 protein normalized to actin (n=3 
replicate wells; interaction p=0.207, genotype p=0.5233, rapamycin p=0.006). (C) Pax6 protein 
normalized to actin (n=3 replicate wells; interaction p=0.665, genotype p=0.0003, rapamycin p=0.415, 
Bonferroni post-test p<0.01) 
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To further explore the relationship between mTORC1 and mTORC2 signaling and neural 
differentiation, we monitored phospho-S6 and phospho-Akt protein levels by immunoblot during the first 
week of neural differentiation using iPS lines CA6, CC3, T20-7 and T16-11. Controls decreased phospho-
S6 levels from day 2 to day 7 suggesting inhibition of mTORC1 activity. However, integrated TSP iPSCs 
also appropriately inhibited mTORC1 (Figure 4.4).  
 
 
Figure 4.4 mTORC1 activity decreases and mTORC2 activity increases during neural 
differentiation of plasmid-reprogrammed iPSCs  
Control iPSC lines (CA6, CC3) and TSP iPSC lines (TSP20-7, TSP16-11) were differentiated to neural 
progenitors. Protein was isolated on Day 2, 5 and 7 of directed differentiation and analyzed by 
immunoblot for phospho-S6 and phospho-Akt (n=2, average of 3 replicate wells for each line). 
 
 
To better isolate the contribution of TSC2 to neural development, we generated isogenic 
homozygous TSC2 knock-out stem cells. Using wildtype and homozygous TSC2 mutant lines we 
differentiated the stem cells towards neural progenitors using dual-SMAD inhibition in adherent cultures 
(neural differentiation protocol #2). We isolated protein and imaged cells weekly during the first four 
weeks of neural development. TSC2 mutant lines display impaired neural differentiation, consistent with 
what we previously observed with heterozygous line T16-11. Protein levels of Pax6, a transcription factor 
upregulated in neural progenitors, increase during the first few weeks of neural differentiation, peaking at 
week 2 in controls. In contrast, the homozygous TSC2-/- cells have lower levels of Pax6 protein, peaking 
at approximately 60% of controls (Figure 4.5A, Figure 4.6). Nestin is an intermediate filament expressed 
in neural progenitors, but it shows a slightly different time course compared to Pax6. The anti-nestin 
antibody detects two bands by immunoblot. Previous reports have suggested that nestin can be 
phosphorylated by cdk5 or cdc2 (Sahlgren et al 2001, Sahlgren et al 2003). The lower nestin band was 
expressed slightly earlier than the upper band (week 1 vs week 2). Although there was no difference 
between wildtype and TSC2 mutant cells in their expression of the lower band, there may be decreased 
expression of the upper nestin band in TSC2 mutant cells (Figure 4.5B p=0.113); however, this did not 
reach significance and further studies will be necessary to determine the identity of the two nestin bands. 
Interestingly, neuronal marker beta-tubulin III, does not show differences between wildtype and TSC2 
mutant cells (Figure 4.5C).  
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Figure 4.5 Impaired formation of neural progenitors from TSC2-/- iPSCs  
Protein was isolated from iPSC-derived neural progenitors over the course of three weeks of directed 
differentiation and analyzed by immunoblot for neuronal markers (A) Pax6 (n=6; interaction p=0.004, 
time p<0.0001, genotype p=0.012 two-way ANOVA; Bonferroni post-test Day 7 p<0.05 Day 14 p<0.001) 
(B) Nestin lower band (n=6; interaction p=0.678, time p=0.001, genotype p=0.441) Nestin upper band 
(n=6; interaction p=0.304, time p=0.0002, genotype p=0.113 two-way ANOVA) (C) β-Tubulin III (n=4) 
52 
 
 
 
Figure 4.6 Expression of neural progenitor marker Pax6 during directed differentiation 
Expression of neural progenitor marker Pax6 was analyzed by immunofluorescence imaged at 10x 
magnification on day 14 and day 23 of neural differentiation 
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Figure 4.7 Changes in mTORC1 and mTORC2 signaling during neural differentiation of iPSCs  
Protein was isolated from iPSC-derived neural progenitors over the course of three weeks of directed 
differentiation and analyzed by immunoblot. (A) pS6/S6 (n=6; interaction p=0.019, time p<0.0001, 
genotype p=0.015 two-way ANOVA; Bonferroni post-test Day 14 p<0.05, Day 21 p<0.01) (B) pAkt/Akt 
(n=6; interaction p=0.251, time p=0.012, genotype p=0.007 two-way ANOVA; Bonferroni post-test Day 
14 p<0.05) (C) p53 (n=6; interaction p=0.002, time p=0.0003, genotype p=0.26 two-way ANOVA; 
Bonferroni post-test Day 7 p<0.01) 
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Figure 4.8 mTORC1 signaling during neural differentiation of iPSCs  
Expression of phospho-S6 was analyzed by immunofluorescence at 10x magnification on day 23 of 
neural differentiation. 
 
Figure 4.9 Impaired early neural differentiation of TSC2-/- iPSCs is mTORC1-independent  
TSC2+/+ and TSC2-/- iPSCs were differentiated to neural progenitors for one week and treated with 
0.2nM rapamycin or vehicle throughout directed differentiation (A) phospho-S6Ser240/244 normalized to S6 
(n=2; interaction p=0.309, rapamycin p=0.354, genotype 0.410, two-way ANOVA) (B) phospho-AktSer473 
normalized to total Akt (n=2; interaction p=0.176, rapamycin p=0.229, genotype 0.286, two-way 
ANOVA) (C) p53 (n=2; interaction p=0.139, rapamycin p=0.054, genotype p=0.066 two-way ANOVA; 
Bonferroni post-test p<0.05) (D) Pax6 (n=2; interaction p=0.041, rapamycin p=0.251, genotype p=0.186 
two-way ANOVA) 
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Next, we explored how mTORC1 and mTORC2 signaling changes during neural development. In 
control cells, mTORC1 signaling, measured by pS6 protein levels, initially drops to 17% of starting day 0 
values before rising to 114% by day 21. In contrast, without tuberin, TSC2-/- cells are unable to decrease 
pS6 as dramatically, and pS6 eventually reaches 220% of day 0 controls by day 21 of neural 
differentiation (Figure 4.7A, Figure 4.8). mTORC2 signaling, measured by phospho-AktSer473, increases 
slightly during neural differentiation in control cells but homozygous TSC2 mutants have decreased 
mTORC2 signaling (Figure 4.7B). Although p53 levels were increased at baseline in homozygous TSC2 
cells, consistent with what was observed previously, both wildtype and TSC2 mutant cells increased p53 
during neural differentiation to similar levels. 
To test whether the increased mTORC1 and decreased mTORC2 signaling were causative in the 
impaired differentiation of homozygous TSC2-/- stem cells, we treated stem cells with the mTORC1 
inhibitor rapamycin during directed differentiation. Rapamycin corrected the abnormalities in mTORC1 
and mTORC2 signaling in homozygous TSC2-/- cells at day 7 of differentiation (Figure 4.9A-B). Further, 
rapamycin partially corrected the elevated p53 protein at day 7 of differentiation (Figure 4.9C). However, 
rapamycin did not correct Pax6 protein levels in TSC2-/- cells. In fact, Pax6 protein was slightly 
decreased in controls, likely due to slowed growth. However, these results are from one round of 
differentiation and will require replication. 
 
Discussion 
 
To explore the effects of heterozygous and homozygous TSC2 mutations on early 
neurodevelopment, we generated heterozygous and homozygous TSC2 iPSCs and then directed them 
towards a neural progenitor fate. Integrated TSC line T16-11 displayed impaired formation of Pax6 
positive neural progenitors despite appropriately exiting the stem cell state. Unlike increased p53 protein, 
loss of p53 in mice does not cause alterations in neural development, so it is more likely that this 
phenotype is due to mutations in the TSC genes or an interaction between the two genes. Alternatively, 
given the results in Chapter II, it is likely that spontaneous differentiation of T16-11 before neural 
induction even began impaired the efficiency of neural differentiation. However, formation of neural 
progenitors was also inhibited in isogenic homozygous TSC2 lines, supporting altered neural 
differentiation regardless of gene dosage. Surprisingly, inhibition of mTORC1 activity with rapamycin 
failed to rescue formation of neural progenitors at day 7 in either heterozygous or homozygous TSC lines. 
However, in both experiments rapamycin appeared to slightly inhibit formation of neural progenitors in 
controls as well. This could be due to slowed growth delaying emergence of Pax6 positive cells. Future 
studies using a longer time course will be required to determine whether the decrease in neural 
progenitors with rapamycin treatment is actually just a delay in the neural differentiation time course. The 
ability of homozygous TSC mutant lines to form early β-tubulin III+ neurons despite decreased neural 
progenitor formation suggests that TSC2 cells may be moving rapidly through the neural progenitor stage 
to produce early neurons rather than expand the neural progenitor pool. Future studies will be necessary 
to track Pax6 positive cells as they divide and differentiate and to explore what cell types the Pax6 
negative cells are forming. 
Costa et al. showed decreased formation of post-mitotic neurons from neural progenitors in both 
heterozygous and homozygous TSC2 human stem cells, suggesting that TSC mutant cells form fewer cells 
at every stage of neural differentiation (Costa et al 2016).This is consistent with our hypothesis that TSC2 
mutant cells undergo increased differentiation at the expense of self-renewal. Interestingly, they were also 
unable to rescue the neuronal differentiation phenotype with rapamycin treatment. Given these results, the 
dominant effect of rapamycin during neural differentiation is likely slowed proliferation, pointing to the 
need for different or more precisely timed treatments. 
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The double band observed when analyzing the neural progenitor marker nestin by immunoblot 
was an interesting finding because each band had a slightly different time course and differences in the 
homozygous TSC2-/- lines were only seen in the upper band. We hypothesize that this larger band may 
represent a phosphorylated form of nestin. Nestin can be phosphorylated by cdc2 or cdk5 (Sahlgren et al 
2001, Sahlgren et al 2003). While the developmental significance of nestin phosphorylation is unclear, 
cdk5 has been shown to be essential for normal cortical development and its activity is highest in post-
mitotic neurons (reviewed in (Lopes and Agostinho 2011). Interestingly, cdk5 is upregulated in cortical 
tubers and SEGAs in TSC while cdc2 is decreased in patient fibroblasts (Ess et al 2004, Ess et al 2005, 
Wataya-Kaneda et al 2001). Elevated cdk5 would be expected to result in increased phospho-nestin but in 
our experiments, we observed decreased expression of the larger nestin band. Additional studies are 
needed to confirm that the larger band we are observing is the phosphorylated form and how TSC is 
affecting nestin regulation.  
Homozygous TSC2-/- iPSCs are unable to regulate mTORC1 and mTORC2 activity during neural 
development. No differences in mTORC1 or mTORC2 signaling are observed in TSC2-/- iPSCs in 
mTeSR due to the high concentration of stimulatory signals; however, neural differentiation media is 
similarly replete with growth factors and glucose. Despite this fact, we did find differences in mTORC1 
and mTORC2 signaling in TSC2-/- lines, suggesting that neural stem cells are especially sensitive to loss 
of tuberin. 
Although different neural differentiation methods and different TSC stem cell lines were used, the 
results between both experiments were consistent. Both experiments showed a decrease in phospho-S6 
levels during early neural differentiation. Both heterozygous and homozygous TSC2 mutant lines had 
impaired differentiation to Pax6 positive progenitor cells, but with no apparent defect in β-tubulin III 
neuron formation in the homozygous TSC2 lines. However, if the stem cells are undergoing 
differentiation at the expense of self-renewal then we expect that TSC2 neural progenitors will form fewer 
β-tubulin III+ neurons over a longer time course. Future studies using TSC iPSCs to dissect neural 
progenitor proliferation versus differentiation will advance our understanding of how TSC2 is regulating 
neural progenitor dynamics. Furthermore, using heterozygous and homozygous TSC2 iPSCs we can begin 
to model loss-of-heterozygosity and non-cell autonomous mechanisms of neural dysfunction. 
 
Materials and Methods 
 
Neural Differentiation Protocol #1 
 Protocol modified from (Neely et al 2012). Cells were isolated using Accutase, counted and re-
plated at 7E4 cells/24 well in mTeSR with rock inhibitor. Once cells reach 80-90% confluency the media 
is switched from mTeSR to neural differentiation media. Neural differentiation media: 41 ml KO 
DMEM/F12, 7.5 ml KO serum replacement, 0.5 ml L-glutamine, 0.5 ml pen-strep, 0.5 ml non-essential 
amino acids, 0.193 μl BMe plus 0.5 μM DMH1 and 10 μM SB431542. 
Neural Differentiation Protocol #2 
 Protocol modified from (Shi et al 2012a, Shi et al 2012b). Cells were isolated using Accutase, 
counted and re-plated at 1E6 cells/12 well in mTeSR with rock inhibitor. Once cells reach 80-90% 
confluency the media is switched from mTeSR to neural induction media. Change media daily. Pass each 
well of 12-well to one 6-well on day 8 using Dispase. On day 11 cells were switched from neural 
induction media to neural maintenance media. Supplement media with 20 ng/ml FGF2 on days 16-18. 
Pass cells 1:3 to three wells of 6-well plate on day 20 using Dispase. 
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Neural differentiation media:  
DMEM/F12 GlutaMAX 242.5 ml 
Neurobasal 241.25 ml 
N-2 (100x) 2.5 ml 
B-27 (50x) 5 ml 
2.5 µg/mL insulin (4 mg/mL stock) 312.5 ml 
1.5 mM l-glutamine (200 mM stock) or glutamax 3.75 ml 
100 uM NEAA 2.5 ml 
10 uM BME (1.43M) 1.75µl 
50 U/mL penicillin + 50 mg/mL streptomycin 5ml 
 For neural induction, supplement neural maintenance media with SMAD inhibitors 2 µM DMH1 10 µM 
SB431542. 
 
Immunoblotting 
Protein was isolated by lysing and scraping cells in RIPA buffer plus protease inhibitor cocktails 
2 and 3 and phosphatase inhibitor cocktail (Sigma P5726, P0044, P8340). Samples were rotated for 30 
minutes at 4°C, sonicated and then run on 4-12% NuPAGE BisTris gels in MOPS buffer. Gels were 
transferred to PVDF membrane at 95V for 90 minutes using the Bio-Rad Mini Trans-Blot Cell. 
Membranes were incubated overnight in primary antibody diluted in 5% BSA. Membranes were then 
incubated for 1 hour at room temperature in secondary antibody and imaged on an Odyssey Li-Cor 
machine. Samples were normalized to actin or to total protein measured using Li-Cor REVERT stain. To 
control for intra-experimental differences in antibody concentration and Odyssey machine settings, 
normalized values are expressed as a percentage of the controls before averaging experimental replicates. 
Statistics 
All statistical analyses were conducted using GraphPad PRISM. Unless otherwise noted, 
individual patient-derived iPSC clones are treated as independent n. All other experimental or technical 
replicates are considered not independent and are averaged to obtain the final value for each patient 
clone/line. Four isogenic clones (two TSC2+/+, two TSC2-/-) were generated using CRISPR-Cas9. For 
experiments involving isogenic lines, both experimental and clone replicates are considered independent 
repeats and are shown in the data. 
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CHAPTER V  
 
PATHOGENESIS AND TREATMENT OF TSC 
 
TSC is a pediatric disorder which frequently causes debilitating intellectual disability and 
refractory epilepsy. Despite the fact that clinicians can diagnose TSC prenatally, there are still limited 
treatment options to offer. Considerable progress has been made since the identification of the TSC1 and 
TSC2 genes in 1993 and 1997. The identification of the TSC complex as a regulator of the mTOR 
pathway led to much hope for the effectiveness of mTORC1 inhibitors in the treatment of disease. 
However, many questions remain including when to treat, what cell types need to be targets, and how 
mutations in TSC1 or TSC2 alter early development. In this chapter, I will summarize findings to date 
using human stem cells with TSC mutations and speculate how the results fit into our understanding of 
the pathogenesis of neurological dysfunction in TSC. 
 
Mechanisms of Cortical Dysfunction in TSC 
 
Hamartomas in TSC are generally thought to arise from a “second-hit” somatic mutation in the 
other allele of TSC1 or TSC2, resulting in excess mTORC1 activity in the affected cell but leaving the 
surrounding heterozygous tissue functionally normal. Accumulating evidence suggests few cells in the 
cortex of TSC patients acquire a second-hit. As most cells in the patients’ brains apparently only harbor 
heterozygous mutations, it is very important to consider alternative hypotheses. First, heterozygous loss 
of TSC1 or TSC2 may be sufficient to alter cell dynamics and mTORC1 signaling. This could be in 
response to specific triggers (removal of growth factors or DNA damage), could occur in specific cell 
types or time points (neural progenitors) or might occur only in precise subcellular compartments 
(lysosome, nucleus neuronal axon). Second, non-cell autonomous mechanisms could be causing 
formation of tubers and disrupting neurodevelopment. Small numbers of cells with loss of heterozygosity 
(e.g. some giant cells within the tubers) could be secreting factors which disrupt neighboring 
neurodevelopment. Further, given our findings of increased p53 and apoptosis, the cells with loss of 
heterozygosity may die at a higher rate, making detection even more difficult. Notably, these possibilities 
are not mutually exclusive. 
Long-term goals of the TSC community include defining the cellular response to stress and 
potential environmental exposures contributing to the variability in disease presentation (Sahin et al 
2016). Cellular reprograming is a stress-filled process; it requires transcriptional and epigenetic 
modifications as well as increased proliferation and a metabolic shift from oxidative phosphorylation to 
glycolysis and further subjects the cells to DNA damage and replicative stress (Firas and Polo 2017, Hsu 
et al 2016, Ruiz et al 2015). In the process of generating TSP iPSCs we discovered that heterozygous 
TSC2 mutant cells are more sensitive to reprogramming stress than control fibroblasts, such that they 
have a higher rate of integration and decreased reprogramming efficiency. We further showed that TSP 
fibroblast and stem cells had an exaggerated response to DNA damaging agents, UV light and 
neocarzinostatin, increasing p53 levels above the wildtype response. Environmental stress or growth 
signals (DNA damage, growth factors, and nutrients) feed into the mTORC1 pathway. During 
development, heterozygous cells may be exposed to an environmental “second-hit” which alters cellular 
differentiation. Our results strengthen the hypothesis that heterozygous cells are not normal and, as such, 
could be contributing to disease manifestations in TSC. 
Given the number of upstream stimuli that feed into mTORC1, it is logical that appreciable 
signaling differences following TSC1 or TSC2 mutations are context dependent. Even our homozygous 
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TSC2-/- stem cells did not display differences in mTORC1 signaling until they were nutrient starved or 
differentiated towards neurons. We showed that following UV damage there may be increased phospho-
S6 in the nucleus of TSC2+/- fibroblasts. Subcellular localization of the TSC complex and mTORC1 is 
critical to its function (Menon et al 2014). Thus, while heterozygous mutations in TSC1 or TSC2 may not 
appear to cause dramatic differences in mTORC1 signaling, the subcellular distribution of the TSC 
complex or downstream effectors could affect cellular function. The localization of the TSC complex may 
be especially important in neurons which contain multiple discrete compartments. Previous studies have 
shown that mTORC1 signaling is elevated in axons and tuberin/mTORC1 components are preferentially 
localized to the axons but not dendrites of neurons (Choi et al 2008, Nie et al 2010).  
 Hamartomas in TSC follow a different developmental timeline depending on the affected organ. 
The onset of hamartomas varies from prenatal to post-puberty and while some regress others continue to 
grow. These differences point to differences in the tissue specific pathogenesis of TSC lesions. Cortical 
populations, in particular, appear to be especially sensitive to TSC mutations. While formation of AML 
and SEGA hamartomas requires a second-hit, the cortical tubers and white matter abnormalities 
apparently do not. Understanding these tissue-specific differences is critical to treating TSC effectively. 
The goal of treatment of AML or SEGA may be to paradoxically increase enhance cellular dysfunction in 
homozygous cells to increase cell death and eliminate the growing hamartoma. Meanwhile, treatment of 
the neurological symptoms may require inhibiting mTORC1, but only in subsets of cells during a specific 
developmental time periods.  
Mouse models have confirmed that mutations of Tsc1 or Tsc2 can alter learning, social 
interaction and neuronal morphology. However, there are dramatic differences between mouse cortical 
development and human cortical development. The mouse cortex develops in the classical inside-out 
layering with progenitors in the ventricular zone and intermediate progenitors in the subventricular zone. 
In contrast, human cortex develops two separate bands of proliferating progenitors- the ventricular 
zone/inner subventricular zone and the outer subventricular zone. It is thought that this additional layer of 
intermediate progenitors contributes to the increased size of human cortex. Secondly, the human cortex 
develops much more slowly than mouse cortex. It takes the mouse 9 days (E9-E18) to develop 
progenitors and all six cortical layers; in contrast, it takes humans 25 weeks. Fortunately, these 
differences in timing and layering are at least partially conserved in cell cultures of mouse and human 
stem cells differentiating to neurons (van den Ameele et al 2014). Human iPSCs then represent an 
opportunity to overcome species-specific differences to enable more valid modeling of early 
neurodevelopment in TSC. 
iPSCs also allow an opportunity to define specific time points during neurodevelopment that are 
sensitive to TSC1/2 mutations. Using wildtype cells, we showed that mTORC1 signaling decreases during 
the first few weeks of directed differentiation. As the TSC complex is the major mTORC1 inhibitor, the 
transition to neural progenitors may be especially sensitive to loss of functioning tuberin and hamartin 
proteins. Indeed, when we differentiated TSC2-/- cells to neural progenitors they had increased mTORC1, 
increased p53 and decreased mTORC2 signaling. Further, homozygous cells had impaired formation of 
neural progenitors. We found similar results in our plasmid-reprogrammed integrated lines. Interestingly, 
rapamycin failed to rescue neural progenitor differentiation at one week despite correcting mTORC1, 
mTORC2, and p53 signaling. Future studies will be required to confirm the phenotype in non-integrated 
heterozygous lines and measure subcellular localization of the TSC complex during neural development. 
Further, immunofluorescent studies are necessary to determine whether TSC mutations are changing 
neural progenitor number or organization.  
Although homozygous mutations in Tsc1 or Tsc2 are embryonic lethal in mice (Kobayashi et al 
1999, Onda et al 1999), second-hits in a small subset of cells or occurring later in development could 
survive long enough to disrupt neighboring cell development. Mice lacking Tsc1 only in neurons have a 
reduction in myelin production and fewer mature oligodendrocytes. The authors then confirmed that 
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neuronal cultures from mice with knockdown or knockout of TSC1/2 and patient iPSC-derived neurons 
secrete more CTGF (connective tissue growth factor) which blocks oligodendrocyte maturation (Ercan et 
al 2017). This is consistent with decreased myelin and oligodendrocytes observed in cortical tubers 
(Muhlebner et al 2016, Scholl et al 2016). Further, it provides evidence for a secreted factor regulated by 
TSC1/TSC2 function which could disrupt cortical development in a non-cell autonomous manner. 
A potential non-cell autonomous mechanism could be further explored using the heterozygous 
and homozygous TSC1/TSC2 iPSCs we generated. Do homozygous neurons secrete signaling molecules 
at baseline or in response to injury/stress? Do heterozygous cells respond to secreted factors in the same 
way as wildtype cells? These studies would begin to answer questions about potential non-cell 
autonomous mechanisms contributing to TSC pathology. 
Costa et al. generated homozygous and heterozygous TSC2 neural stem cells from hESCs (Costa 
et al 2016). When the neural stem cells were differentiated to post-mitotic neurons, heterozygous and 
homozygous cells formed fewer post-mitotic neurons in a dose dependent manner. They also observed an 
increase in cell death in differentiating homozygous TSC2-/- neural stem cells. This along with our 
findings of increased p53 and impaired formation of neural progenitors suggests that homozygous TSC2 
mutant cells have increased apoptosis at multiple stages of neural development. This may help explain 
why second-hits are so rare in cortical cells but it leads to more questions. Are neurons more sensitive to 
loss of TSC2? What are the tissue specific differences that allow for formation of hamartomas without 
loss-of-heterozygosity in the cortex but not in the kidney? Future studies using iPSC-derived cells 
representing the major organs affected in TSC will begin to answer questions about the tissue specific 
pathogenesis of TSC. 
 
Treatment of TSC 
  
TSC is a heterogeneous disorder affecting multiple organs and causing diverse symptoms. When 
the TSC1/2 genes were discovered and shown to inhibit mTORC1, it was hoped that mTORC1 inhibitors 
would be able cure TSC. Although mTORC1 inhibitors are effective at treating some aspects of the 
disease, such a varied disease may require multiple treatment options. 
mTORC1 inhibitors have robust inhibiting effects on cell proliferation and growth in vitro and in 
vivo. This has been employed to successfully treat kidney AMLs or the SEGA brain tumors. However, 
this appears to be a static therapy as benefits are limited to the treatment period; once mTORC1 inhibitors 
are discontinued hamartomas begin to regrow. These limitations suggest that perhaps our goal in 
treatment of AML and SEGA should not be to transiently reverse the phenotype but instead to kill the 
proliferating cells. AMLs and SEGAs have acquired a second-hit resulting in excess mTORC1 activity, 
growth and proliferation. By treating these cells with mTORC1 inhibitors, clinicians may be shifting the 
cells back towards a more normal phenotype while exposed to the drugs. Cells then stop expanding and 
multiplying but the TSC complex is still absent and unable to appropriately regulate mTORC1 activity. 
Once the “brakes” are removed from mTORC1, cells will return to expanding and proliferating. An 
alternative strategy then may be to drive these hyper-proliferative cells towards cell death either through 
coupling mTORC1 inhibition with additional medications, a strategy frequently employed in cancer 
treatment, or through entirely new targets. 
Given our results suggesting increased sensitivity to cell death and apoptosis in cells with 
mutations in TSC1/2, a potential new therapeutic approach would be to enhance the apoptotic phenotype 
in AMLs and SEGAs. Using heterozygous and homozygous TSC1/2 iPSCs, we could screen for 
treatments which increase cell death in homozygous but not heterozygous cells. An ideal treatment would 
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kill homozygous TSC1/2 cells in AMLs and SEGAs without damaging the heterozygous cells which 
make up the majority of the patient’s body. 
TSC patients have a high rate of epilepsy (75-85%) and frequently develop refractory epilepsy 
(Chu-Shore et al 2010, Jones et al 1999). Furthermore, most patients present with seizures within the first 
year and cognitive outcomes are correlated with age of onset (Chu-Shore et al 2010). Treatment of 
epilepsy and neurocognitive disorders would significantly improve outcomes in TSC patients. 
Unfortunately, the use of mTORC1 inhibitors in the treatment of TSC-related epilepsy is less well 
supported by clinical trials. The first trial published in 2013 reported a reduction in seizure frequency in 
17 out of 20 patients who had a history of refractory epilepsy (Krueger et al 2013). A subsequent study, 
the EXIST-1 trial, found no difference between the treatment and placebo arm; however, as seizure 
frequency was not the primary endpoint of that study the patients were not balanced appropriately 
between the two arms, complicating interpretation (Franz et al 2013). These results suggest that the 
mechanisms of epilepsy as well as neurocognitive symptoms of TSC may be different than the excessive 
growth of AMLs and SEGAs. These differences could be related to gene dosage effects or developmental 
differences.  
If ongoing research uncovers evidence to support a non-cell autonomous mechanism of cortical 
dysfunction then it may be possible to target the homozygous dysfunctional cells using a similar strategy 
as AMLs and SEGAs. However, even if eliminating the disruptive homozygous TSC1/2 mutant cells 
would cure the neurocognitive symptoms, we would need a better understanding of when during 
development to target these cells. The fact that tubers are formed prenatally suggests that the pathological 
events are occurring early in development. Our results support the idea that there may be developmental 
time points especially sensitive to changes in TSC1 or TSC2.  
However, since the majority of the cortical cells in TSC patients are heterozygous TSC1/2 cells 
the goal would be to correct the phenotype rather than eliminate offending cells. Our and other’s results 
suggest that mTORC1 inhibitors may not be able to correct the abnormal neural differentiation in TSC. 
The overwhelming cytostatic effect of rapamycin may be obscuring any beneficial effect on 
developmental pathways. Inhibitors or activators targeting a subset of downstream effectors of mTORC1 
(i.e. S6K, 4EBP1, autophagy) may be required to correct neurodevelopmental phenotypes. However, 
other studies have shown rescue of abnormal excitability in iPSC-derived neurons, suggesting there may 
be some hope for treatment even without correcting early developmental abnormalities (Costa et al 2016). 
 
Summary 
 
Human iPSCs will allow us to answer questions about the basic function of TSC1 and TSC2 in 
multiple developing tissue types but most especially in neural progenitors. Understanding when during 
development and in what cell types cellular dysfunction first occurs will allow for much more targeted 
and effective therapies in patients. The clinical presentation of TSC is highly variable even among 
patients with identical gene mutations. Using iPSCs to model TSC offers great potential as a method to 
address genotype-phenotype correlations and potential modifiers. Much of the promise of patient-derived 
iPSC technology is hampered by the inherent variability of lines from different individuals. Use of 
CRISPR-Cas9 to generate isogenic lines either by replicating the mutation in a wildtype line or correcting 
the mutation in a patient line will overcome many of these limitations. Defining a robust phenotype in 
isogenic lines is the first step to then analyzing differences in individual patient lines. The goal is to not 
only understand more about the basic biology of TSC, but to be able to use patient iPSC lines to predict 
disease severity and response to various treatments. 
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APPENDIX 
 
Figure 5.1. Immunoblot of fibroblast time course response to UV challenge  
Fibroblast lines were exposed to UV light and protein isolated at 0, 8 16, and 24 hours post-exposure was 
analyzed by immunoblot. Protein levels were normalized to total protein. 
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Figure 5.2 mRNA, translation and stability of p53 in fibroblasts 
(A) mRNA levels of TP53 in fibroblasts were measured by qPCR at baseline using primers directed to the 
5’ end. Samples were normalized to ACTIN and PGK1. (n=3, p=0.395, t-test) (B) Fibroblasts were 
challenged with UV light and RNA was isolated 24 hours later. Levels of TP53 mRNA were measured by 
qPCR using primers directed to the 5’ end (n=3, genotype p=0.056, t-test) (C) Fibroblasts were treated 
with the proteasome inhibitor MG132 (1 μM) for 6 hours with or without UV challenge. p53 protein 
levels were analyzed by immunoblot. (D) Fibroblasts were challenged with UV light and 15 hours later 
treated with the translation inhibitor cycloheximide (100 μM) for two hours. p53 protein levels were 
analyzed by immunoblot. 
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Figure 5.3 Immunoblot of TSC2 heterozygous and homozygous stem cells  
(A) Non-integrated iPS lines generated from TSC2 heterozygous patient fibroblast lines treated with the 
DNA damaging agent neocarzinostatin for 1 hour show increased p53 relative to controls. (n=6, 1-3 
experimental repeats per sample; p=0.04 t-test) (B) Homozygous TSC2-/- and isogenic control stem cells 
were nutrient starved for 2.5 hours in DMEM without glucose or HBSS media. Protein levels of pS6 were 
elevated in TSC2-/- iPS cells following nutrient starvation. (n=4, 2 clones with 2 experimental repeats; 
p=0.0002 t-test) 
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